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Introduction 
Scope of the thesis 
This thesis addresses the long-term perspectives of type 2 diabetes mellitus in a Dutch 
general practice setting. Firstly, we studied the impact of type 2 diabetes mellitus on life 
expectancy and quality of life. Secondly, we assessed the long-term effectiveness of 
treatment after the introduction of an audit-enhanced monitoring system. This monitoring 
system selects patients that need special attention: patients with poor glycaemic control 
despite maximum oral medication. These patients entered an intervention study: initiation of 
insulin therapy. In addition we studied the value of microalbuminuria in the monitonng of 
type 2 diabetic patients in general practice. We described the course of microalbuminuria 
over 6 years follow-up and the predictive value of microalbuminuria on mortality. 
Type 2 diabetes mellitus 
Type 2 diabetes mellitus is probably one of the most complex diseases managed in primary 
care. The disease is characterised by sustained elevated blood glucose levels. This chronic 
hyperglycaemia is associated with a number of long-term complications: retinopathy with 
potential loss of vision, nephropathy with potential renal failure, peripheral neuropathy with a 
risk of foot ulcers and amputation, autonomic neuropathy with potential gastrointestinal, 
genitourinary and cardiovascular problems and sexual dysfunctioning Especially type 2 
diabetic patients have an increased risk of artherosclerotic cardiovascular and 
cerebrovascular morbidity and mortality. The emotional and social impact of diabetes and the 
demands made by therapy may cause psychosocial dysfunctioning in the patients and their 
families. 
Pathophysiology 
Type 2 diabetes mellitus is caused by a combination of insulin resistance and a defect in 
insulin production. Reaven suggested the existence of a syndrome in which insulin resistance 
is the primary defect, associated with compensatory hyperinsuhnaemia, called Syndrome X.1 
He postulated that the cluster of changes associated with resistance to insulin-mediated 
glucose uptake make up a syndrome, which plays an important role in the etiology and 
clinical course of patients with non-insulin-dependent diabetes, high blood pressure and 
coronary disease. In this hypothesis the apparent ability of ambient hyperinsuhnaemia to 
prevent decompensation of glucose homeostasis in insulin-resistant individuals does not 
mean that the resulting state is benign, as insulin resistance and hyperinsuhnaemia are 
involved in the genesis of both hypertension and cardiovascular morbidity.23'1 In subsequent 
years, the role of insulin resistance was further explored5,0 and discussed.7'8'9'10'" As a 
consequence, treatment for diabetes no longer focused on glycaemic control alone, but also 
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included systematic monitoring of cardiovascular risk factors, such as smoking, blood 
pressure and lipids. 
Prevalence 
A level of hyperglycaemia sufficient to cause damage to vanous tissues may be present long 
before diabetes is detected.12 Type 2 diabetes is not usually diagnosed before the age of 40 
years. Studies from general practice showed that about 1.5-2% of the Dutch population have 
type 2 diabetes,13'14 while in all probability, another 2% are affected but unrecognised.15 In 
1995, the estimated prevalence of diabetes among adults was 7.4%; the prevalence is 
expected to nse to 8.8% by 2025.1 6 Incidence and prevalence increase with age (figures 1-1 
and 1-2). Despite the high prevalence and the fact that most type 2 diabetic patients are 
treated in general practice, very few data are available about the long-term course of type 2 
diabetes in general practice. 
Figure 1-1 Incidence of type 2 diabetes mellitus per 1000 patient-years in the Continuous 
Morbibity Registration Nijmegen, 1994-1998. 
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Background of the thesis 
Since the meeting of the World Health Organisation and the European section of the 
International Diabetes Federation in 1989 in Saint Vincent, Italy, European health care 
politicians, patient organisations and diabetes experts have agreed on the goals for the quality 
of diabetes care m Europe: the so-called St Vincent Declaration.18 The declaration is very 
bnef (one page) which probably heightened its impact. It was based on the idea that 
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improving the quality of diabetes care will improve the outcome of diabetes care. European 
and Dutch guidelines were developed to stimulate improvement in diabetes care. 
However, it remained uncertain whether improved care resulted in improved control and 
whether the new approach helped to prevent or postpone diabetes-related complications. 
Many observational studies have shown that the incidence and progression of especially 
microvascular complications, is related to glycaemic control. 21.22,23.24.25,26,27.28 A positive, but 
rather weak association was found between blood glucose control measures and the risk of 
mortality in type 2 diabetic patients.29 However, observational studies do not yield 
information about causal relations. Therefore we looked for the results of two recently 
published randomised controlled trials (RCTs). 
Figure 1-2 Prevalence of type 2 diabetes mellitus per 1000 patient-years in the Continuous 
Morbidity Registration Nijmegen, in 1998. 
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First, the United Kingdom Prospective Diabetes Study (UKPDS) aimed to determine whether 
improved blood glucose and/or blood pressure control would prevent complications and 
reduce associated morbidity and mortality.30 In addition, the UKPDS investigated the effects 
of sulphonylurea, which was reported to induce cardiac death in earlier studies. The 
UKPDS study showed that an intensive glucose-control treatment policy resulted in an 11% 
lower HbAlc, i.e. a median of 7.0% over the first ten years after diagnosis. This reduced the 
frequency of microvascular endpoints, but not the frequency of diabetes-related mortality or 
cardiovascular mortality.33 There was no evidence that intensive treatment with 
chlorpropamide, glibenclamide or insulin had specific adverse effecls on macrovascular 
disease. In contrast with the intensive glucose control, tight blood pressure control achieved a 
clinically important reduction in the nsk of diabetes-related mortality and morbidity.34 
Epidemiological data from the UKPDS showed that there were no natural thresholds under 
which the risk of microvascular and macrovascular complications would fully be prevented, 
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but the risk increased steadily with rising levels of glycaemia and blood pressure. 
However, as an observational cohort analysis approach was employed the analysis was 
inevitably subject to bias.37 
A second trial, the 4S study, provided evidence that lowering cholesterol reduces the risk of 
mortality and cardiovascular morbidity in diabetic patients with coronary heart disease.38 A 
post hoc subgroup analysis showed that over a 5.4-year median follow-up period, simvastatin 
treatment produced mean changes in serum lipid concentrations in diabetic patients that were 
similar to those observed in non-diabetic patients. The relative risk of major cardiovascular 
events in patients treated with simvastatin was significantly reduced (RR 0.45). Total 
mortality was clinically but not statistically significantly reduced (RR 0.57, p=0.08). 
It should be emphasized that RCTs have fundamental limits. By definition, they are 
conducted under 'experimental' conditions (efficacy) which means that the results cannot be 
directly extrapolated to clinical practice (effectiveness). It remains to be seen whether the 
results of the UK.PDS and 4S can be reproduced in normal daily GP care (effectiveness).39,40 
To investigate the extent to which evidence from RCTs can be translated and implemented 
into routine clinical practice, observational health care assessment studies are needed. For 
diabetes, it has been recommended that diabetes centres continuously assess the outcome of 
their care on a patient level and publish their results.41 
So far, most general practice studies have provided information on the process, but not on 
outcome. These studies have shown clearly that the quality of care depends on its structure: 
patients should be systematically recalled, time must be allocated and a management protocol 
must be followed.4241 Unfortunately, there are no data about the long-term outcome of 
diabetes care in general practice. 
Aims of the thesis 
The aims of this thesis were: 
1. To assess the long-term impact of type 2 diabetes mellitus on cardiovascular morbidity 
and mortality and functional health status. 
2. To assess the long-term outcome of diabetes care after the introduction of an audit-
enhanced monitoring system for type 2 diabetic patients in an academic general practice 
research network. The impact of insulin therapy on quality of life was studied in patients 
with poor glycaemic control, despite maximum oral medication. 
These aims raised two other methodological research issues. 
The first issue was related to the selection of controls. Controls for clinical studies are usually 
matched to index patients on demographic characteristics (sex, age, race, place of birth, 
family composition, etc ) while excluding those with the clinical condition under study. 
Although the importance of the presence or absence of clinical features in the controls is 
generally acknowledged, few empmcal data are available about the effects. Therefore we 
used the Continuous Morbidity Registration database to quantify the effects of varying the 
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case mix of participants. Controls were matched to cases on illness behaviour (frequency of 
consulting the general practitioner), chronic psychosocial problems, cardiovascular 
morbidity, and the degree of severity of comorbid conditions. 
The second issue involved selecting the most appropriate indicators for the audit-enhanced 
monitoring to measure process and outcome of diabetes care in a general practice setting. For 
this purpose we selected microalbuminuria to monitor type 2 diabetic patients. This resulted 
in two studies: 
a. the first evaluated the role of a semiquantitative dipstick test to screen for 
microalbuminuria in type 2 diabetic patients in general practice; 
b. the second assessed the course of microalbuminuria in type 2 diabetic patients in general 
practice and evaluated the predictive value of urinary albumin concentration for all cause 
mortality, cardiovascular mortality and cardiovascular morbidity 
Structure of the thesis 
Long-term impact of type 2 diabetes mellitus in general practice 
We analysed overall mortality, cardiovascular mortality and cardiovascular morbidity in a 
cohort of type 2 diabetic patients from the Continuous Morbidity Registration Nijmegen 
(CMR) during an observation period of up to 22 years (chapter 2a). Data were also obtained 
from a matched control group of non-diabetic patients. This was the first long-term 
prospective study on the natural course of type 2 diabetes mellitus in the Netherlands. In an 
alternative methodological approach we investigated how different selections of controls 
affected the outcome {chapter 2b). 
As we expected that the higher incidence of cardiovascular morbidity in type 2 diabetic 
patients would not only influence life expectancy, but also quality of life, we compared 
functional health and quality of life between type 2 diabetic patients and a non-diabetic 
control group (chapter 3). 
Audit-enhanced monitoring 
To support structured diabetic care in daily general practice an audit-enhanced monitoring 
system was developed and introduced at the 10 general practices of the academic research 
network of the Department of General Practice (chapter 4). The system enables systematical 
data collection on all type 2 diabetic patients during normal practice routine. The data were 
processed into a feedback report with respect to measures of process and outcome of care, at 
the University Department of General Practice. The outcome of diabetes care under this 
audit-enhanced monitoring system was analysed over a period of seven years (chapter 5). We 
expected that audit-enhanced monitoring would result in: (1) higher compliance to check-up 
visits; (2) better glycaemic control; (3) better control of cardiovascular risk factors, such as 
blood pressure and lipids. The monitoring system also selected patients with poor glycaemic 
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control despite maximum oral medication. We studied the impact of insulin therapy on 
glycaemic control, daily functioning and quality of life in these patients (chapter 6). 
The value of microalbuminuria in the monitoring of type 2 diabetes mellitus 
We assessed the feasibility of screening a large diabetic population for microalbuminuria by 
means of the Micral test in a general practice setting (chapter 7). Over a six year period, the 
course of microalbuminuria was recorded in type 2 diabetic patients in general practice and 
we assessed the predictive value of the baseline urinary albumin concentration on 
cardiovascular morbidity and mortality (chapter 8). 
The Academic Research Network of the Department of Family Medicine 
of the Nijmegen University: CMR/NMP 
Continuous Morbidity Registration Nijmegen (CMR) 
In 1967 the Continuous Morbidity Registration Nijmegen was started at two general practices 
in the Nijmegen region; since 1971 four practices have been involved. Aim of the CMR is to 
provide a scientific basis for general practice. The CMR was founded by professor FJA 
Huygen when he was appointed as the founding chair οι Family Medicine in Nijmegen.45 
The registry holds data on incidence, prevalence and the long-term course of illness in the 
context of an individual's psychosocial and family structure to gain greater insight into the 
epidemiological aspects of diseases and disorders encountered in general practice. 
Currently, the CMR serves as an essential index for long-term follow-up of patients in 
general practice.'"''47 All presented morbidity episodes are entered into the register by the 
general practitioner (GP) and the diagnosis is classified as soon as it is established. All 
diagnoses made by specialists are also recorded. To classify the diagnoses, the adapted E-
list4li is used, with a fourth digit extension to make it compatible with the ICHPPC-2.49 The 
quality and consistency of classification recieve continuous attention. For each patient data 
are available on: sex, date of birth, dale of entry into or removed from the CMR, family 
composition and social class. 
The four practices have a population of approximately 12.000 with a turnover of about 5% 
per year and forni part of the Nijmegen Academic Research Network. 
The Nijmegen Monitoring Project (NMP) 
Experience with the CMR regarding continuous data gathering and patient monitoring 
formed a excellent basis for a project on hypertension monitoring in 1970. General 
practitioners gradually became aware of the importance of regular and long-term care for the 
prognosis of patients with hypertension. The Nijmegen Intervention Project (NIP) explored 
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these issues between 1977 and 1982.50'5' It was found that monitoring and feedback were 
needed to maintain the improvements in care outcome in the long-term. A follow-up system 
with feedback to the participants was developed as a consequence of the NIP experience.52 
The approach of monitoring hypertension was also applied to other common chronic 
diseases. This resulted in the Nijmegen Monitoring Project (NMP). Since 1986, 10 practices 
have been participating, currently with 29 general practitioners, 35 practice assistants and 
about 45,000 patients. Monitonng is directed at patients with hypertension,53'54'55 diabetes 
mellitus and related cardiovascular morbidity, and asthma or chronic obstructive lung 
diseases.56 The aims of this project of systematic monitoring and feedback are twofold: to 
improve the quality of care and to develop a research infrastructure for the study of the long-
term outcome of care for chronic diseases in general practice. Since the start, the NMP has 
formed part of the Nijmegen Academic Research Network and it contributes to the Nijmegen 
research programme on chronic diseases.46 
The current monitoring and feedback of type 2 diabetes mellitus was developed on the basis 
of the studies described in this thesis. 
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Summary 
Objective A historical cohort study was performed to assess cardiovascular morbidity and 
mortality in type 2 (non-insulin-dependent) diabetic patients. 
Patients and Methods The data were collected from 1967 to 1989 in four Dutch general 
practices performing the Continuous Morbidity Registration Nijmegen. Each newly 
diagnosed type 2 diabetic patient fulfilling the WHO criteria (n=265) was matched to a 
control patient for practice, sex, age, and social class. Inclusion started in 1967, the first year 
of the still ongoing. Continuous Morbidity Registration Nijmegen. 
Results On average, a follow-up of 6.8 years (range 1 month - 22 years) was realised. 
Compared to the non-diabetic control patients, the type 2 diabetic patients showed a higher 
cardiovascular morbidity (risk ratio 1.76, 95% CI 1 . 3 4 - 2 30) and a higher mortality rate 
(risk ratio 1.54, 95% CI 1.07 - 2.23). Mortality after 10 years was 36% vs 20% (p<0.01), the 
median survival time 16 years vs 19 years. The cumulative survival rates were significantly 
different (p< 0.01) between patients and controls in the age group 65-74 years. The higher 
mortality in type 2 diabetic patients was completely due to an excess of cardiovascular death 
(nsk ratio 2.05, 95% CI 1.24 - 3.37). 
Conclusion This study clearly demonstrates that type 2 diabetic patients in general practice 
are at higher risk of cardiovascular morbidity and mortality. 
Keywords Type 2 diabetes. Cardiovascular morbidity. Mortality, General practice 
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Introduction 
In the Netherlands, as in the United Kingdom, the majority of type 2 (non-insulin-dependent) 
diabetic patients are treated in general practice.'"3 However, knowledge about type 2 diabetes 
is mainly based on patient groups selected from hospital care It is apparent that type 2 
diabetes can be characterised as a risk factor for cardiovascular disease, particularly for 
stroke,6 ischaemic heart disease,7, and peripheral vascular disease.9 The prevalence of 
hypertension is also higher.10 
Panzram has reported an increased mortality in type 2 diabetes, particularly in females." He 
has stated that mortality statistics on diabetes are frequently biased by factors including 
referral bias in hospital populations. The most reliable results can be expected from 
prospective studies of defined cohorts recruited from general practice population surveys.12 
This paper reports an analysis of cardiovascular morbidity and causes of death in a cohort of 
type 2 diabetic patients from general practice covering an observation period of up to 22 
years. The aim of the study was to assess the impact of cardiovascular morbidity and 
mortality on type 2 diabetic patients in general practice. 
Patients and methods 
Continuous Morbidity Registration Nijmegen 
The ongoing Continuous Morbidity Registration Nijmegen started in 1967 in four general 
practices in and around Nijmegen.11 This registration aims to study the epidemiological 
aspects of diseases in general practice, including the incidence, prevalence, and the course of 
the disease in time. 
Every episode of illness seen by or reported to the general practitioner (GP) is registered as 
soon as it is established. In the Netherlands specialist care is only available after referral by 
the GP, and for the specialist it is a routine procedure to report back to the GP about 
diagnosis and treatment in referred patients. All referrals and specialist-reported diagnosis are 
also recorded in the registration system To register diagnoses the adapted E-list14 is used, 
with a fourth digit extension to make it compatible with the International Classification of 
Health Problems in Primary Care (ICHPPC-2).1 The GPs also register causes of death, 
including those of patients dying in hospital. 
The four practices have a practice population of approximately 12,000. This number has 
remained stable over the years with a turnover of less than 5% per year. For each patient the 
following data are available: sex, date of birth, date of entry or departure in the Continuous 
Morbidity Registration, family composition, and social class. Social class is defined 
according to profession as well as education A validated Dutch list of 11 categories is 
usually reduced to 3 as is the case here. 
16 The Ni/megen Monitoring Project 
Selection of patients and controls 
All newly diagnosed type 2 diabetic patients between 1967 and 1989 (n=265), including 
those who were under specialist medical care, were included in the study cohort if the 
diagnostic evidence was in agreement with the WHO criteria.16 The diagnosis of all cases 
was reviewed using all available data from the patients' files. Patients treated with insulin 
within 1 year of diagnosis and who remained on it were regarded as type 1 (insulin-
dependent) diabetes mellitus. All other patients with diabetes mellitus were considered type 
2, irrespective of their current treatment. 
For each patient a control was selected, matched for practice, sex, age (± 3 months), and 
social class. Controls were selected from all patients on the practice lists at the time of 
diagnosis of the patients with type 2 diabetes, with the exception of patients with known 
diabetes mellitus. There were no further exclusion criteria for controls. Patients and controls 
were followed up for mortality, cardiovascular morbidity, as well as cardiovascular risk 
factors from the time of diagnosis of the type 2 diabetic patient. 
Cardiovascular morbidity included cerebrovascular accident, myocardial infarction, angina 
pectoris, heart failure, and peripheral vascular disease. The following nsk factors were taken 
into account: hypertension, obesity, and hypercholesterolaemia. Mortality was specified 
according to the direct cause of death recorded. 
A control patient developing clinical diabetes during follow-up was included in the study 
cohort. As a consequence two new controls were selected. 
Statistical procedure 
The cumulative incidence rates (first occurrence of the disease) of cardiovascular morbidity 
in the year of diagnosis and after 5, 10, and 15 years as well as mortality rates were 
calculated using the cohort life-table method.17 Statistical analysis was performed using the 
Mantel Haenszel procedure and the Cox Proportional Hazard regression model. Variables 
were entered into the multivariate regression model using the maximum partial likelihood 
ratio method. The data were analysed at the University of Nijmegen by means of the 
Statistical Analysis System (SAS 6.06).'8 
Results 
A total number of 427 patients were registered between 1967 and 1989 as newly diagnosed 
diabetic patients by their GP. In 111 it was not possible to confirm the diagnosis for various 
reasons: in 43 no blood glucose values could be traced in their records (diagnosis and follow-
up had only been based on urine glucose values), in 61 only normal blood glucose levels 
were found or only the criteria for impaired glucose tolerance were met and in 7 the medical 
records were incomplete. 
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The remaining 316 patients met the 1985 WHO-cntena for diabetes mellitus Type 1 diabetes 
mellitus was diagnosed in 35 patients In 9 it remained inconclusive whether they had type 1 
or 2 diabetes, and in 7 other patients a secondary cause of diabetes mellitus was present 
pregnancy in 6 cases and pancreatectomy in 1 
Thus 265 type 2 diabetic patients (112 men (40,3%) and 153 women) were included in the 
study cohort At diagnosis 60% of these were aged 65 or under The mean follow-up was 6 8 
years (range from 0 8 to 22 years) The matching succeeded completely for practice (100%), 
sex (100%), age (100%, range 3 months), and social class (98%) 
Cardiovascular morbidity 
Prevalence at diagnosis and cumulative incidence rates after diagnosis of cardiovascular 
morbidity are presented in table 2a-1 The relative risk amounted to 1 76 (95% CI 1 34 -
2 30) in type 2 diabetic patients compared to controls It was higher in men (1 94, 95% CI 
1 28 2 93) than in women (1 63, 95% CI 1 15 - 2 32) Moreover, 5 years after diagnosis the 
cumulative incidence rates for cardiovascular diseases in this study cohort were already 
significantly higher (p < 0 05) in patients than in controls, except for myocardial infarction 
and peripheral vascular disease 
Data related to cardiovascular risk factors are presented in table 2a-2 A higher prevalence of 
hypertension, obesity, and hypercholesterolaemia were present in patients compared to 
controls already at the time of diagnosis (p < 0 05) 
Mortality 
Within the follow-up period 71 patients and 50 controls died resulting in a relative nsk of 
mortality in type 2 diabetic patients of 1 54 (95 % CI 1 07 - 2 23) compared to controls It 
was more predominant in women (1 61, 95% CI 0 97 - 2 68) than in men (1 47, 95% CI 0 86 
- 2 50) 
The 10-year mortality rates of the patients and controls were 20 % vs 36 % (p < 0 01), the 
median survival time 16 years vs 19 years (figure 2a-1) The cumulative survival rates of 
type 2 diabetic patients turned out to be significantly different (p < 0 01) from those of 
controls in the age group 65-74 (figure 2a-2) 
The majonty of deaths in the patients group were due to cardiovascular disease, accounting 
for 46 of the 71 deaths (64%), with coronary heart disease (32%) as the most prominent 
cause of death (table 2a-3) The relative risk in type 2 diabetic patients of death due to 
cardiovascular morbidity was 2 05 (95% CI 1 24 3 37) compared to controls There was 
only a slight difference between men (2 01, 95% CI 0 95 4 27) and women (2 07, 95% CI 
1 06 - 4 04) 
Table 2a-l Prevalence rates at diagnosis and cumulative incidence rates after diagnosis of cardiovascular morbidity in type 2 diabetic patients 
(n = 265) compared to controls (n = 265), matched for practice, sex, age, and social class. 
Cerebrovascular accident 
Myocardial infarction 
Angina pectoris 
Heart failure 
Peripheral vascular disease 
Total cardiovascular morbidity' 
At diagnosis 
Control 
1 
(3) 
5 
(13) 
6 
(17) 
9 
(24) 
3 
(8) 
19 
(52) 
Type 2 
2 
(6) 
6 
(17) 
13 
(34) 
15 
(40) 
5 
(14) 
24 
(63) 
After 5 
Control 
3 
(6) 
9 
(22) 
13 
(31) 
14 
(34) 
8 
(20) 
30 
(75) 
years 
Type 2 
Τ 
(17) 
14 
(33) 
19' 
(50) 
2 2 a 
(55) 
12 
(27) 
46b 
(115) 
After 10 
Control 
6 
(9) 
13 
(25) 
13 
(32) 
24 
(45) 
10 
(22) 
44 
(91) 
years 
Type 2 
12' 
(22) 
24b 
(45) 
22' 
(52) 
30' 
(65) 
23' 
(38) 
62b 
(138) 
After 15 
Control 
8 
(10) 
20 
(29) 
15 
(33) 
30 
(49) 
11 
(23) 
56 
(100) 
years 
Type 2 
14' 
(23) 
32b 
(49) 
26' 
(54) 
40' 
(70) 
33b 
(43) 
74b 
(148) 
End of study (22 years) 
Risk ratio 
1.34 
1.82 
1.78 
1.52 
2.12 
176 
95% CI 
0.84-2.14 
1.57-2.86 
1.14-2.77 
1.04-2.21 
128-3 51 
1.34-2.30 
Results as peicentage (the absolute number of cases are presented between parentheses) 
Statistical differences were calculated using the log-rank test 
Cox proportional hazard regression was used to calculate risk ratio for type 2 diabetic patients compared to controls 
°p<0 05, 
bp<00i. 
c
 Total cardiovascular morbidity represents all patients with at least one of the cardiovascular diagnoses 
Table 2a-2 Prevalence rates at diagnosis and cumulative incidence rates after diagnosis of cardiovascular risk factors in type 2 diabetic 
patients (n = 265) compared to controls (n = 265), matched for practice, sex, age, and social class. 
Hypertension 
Obesity0 
Hypercholesterolaemiad 
At diagn 
Control 
23 
(61) 
34 
(91) 
3 
(7) 
OS1S 
Type 2 
40a 
(108) 
62b 
(163) 
10a 
(26) 
After 5 
Control 
27 
(69) 
41 
(108) 
6 
(13) 
years 
Type 2 
47b 
(122) 
68" 
(179) 
15b 
(37) 
After 10 
Control 
32 
(75) 
48 
(115) 
6 
(13) 
years 
Type 2 
53b 
(128) 
70b 
(182) 
17b 
(39) 
After 15 
Control 
32 
(75) 
50 
(116) 
8 
(14) 
years 
Type 2 
45" 
(130) 
72b 
(183) 
20b 
(40) 
End of study (22 years) 
Risk ratio 
1.83 
1.91 
2.70 
95% CI 
1.31-2.57 
1.41-2.60 
1.12-6.56 
Results as percentage (the absolute number of cases are presented between parentheses) 
Statistical differences were calculated using the log-rank test 
Cox proportional hazai d regression was used to calculate risk ratio for type 2 diabetes patients compared to controls 
"p<005 
''p<00l 
r
 Bod) mass inde\ >27 kg/height (m~) 
Mean result of three measurements > 7 0 mmol Γ 
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Cox proportional hazard regression analysis of all patients and controls was used to 
determine the independent factors significantly related with mortality. Diabetes itself (p = 
0.02) and pre-existing hypertension (p = 0.02) turned out to be statistically significant factors 
related to mortality. Obesity (p = 0.55) and hypercholesterolaemia (p = 0.63) did not show 
statistical significance. 
Figure 2a-l Survival curves of type 2 diabetic patients m general practice [+] (n - 265) 
and controls [ • ] (n = 265), matched for practice, sex, age, and social class m the period 
1967 — 1989. Within the follow-up period 71 patients and 50 controls died resulting in a 
relative risk of mortality in type 2 diabetic patients of 1.54 (95% CI 1 07 - 2.23) compared to 
controls. The 10-year mortality rates of the patients and controls were 20 % vs 36 % (p < 
0.01), the median survival time 16 years vs 19 years. 
20 
controls 
type 2 diabetic patients 
5 10 15 
years after diagnosis 
20 
Discussion 
This study clearly demonstrates that type 2 diabetic patients in general practice are at higher 
nsk of cardiovascular morbidity and mortality. The latter was more predominant in women 
than in men. In both sexes the excess mortality was completely due to an excess in 
cardiovascular mortality. Population-based studies have reported an approximately two-fold 
excess nsk of all causes of death and a two- to four-fold excess risk from cardiovascular 
diseases among diabetic patients." The majority of these studies gave excess mortality rates 
that were higher in women than in men.19"23 Other studies showed a higher excess mortality 
in type 2 diabetic men compared to women.24"26 However, there were no such data available 
from general practice. Moreover, the different methodological approaches in the design of 
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Figure 2a-2 Survival curves for three age categories of type 2 diabetic patients [ ] in 
general practice and controls [ ], matched for practice, sex, age, and social class in the 
period 1967 - 1989. The survival rates of type 2 diabetic patients turned out to be 
significantly different (p < 0.01) from those of controls in the age group 65 - 74 [ • ] (n = 
77) In the age group 45 - 64 years f+J (n = 114) statistical significance was not reached 
due to shortage of follow-up. In the age group over 75 years [UJ(n = 52) it is age itself that 
has become the most powerful predictive factor. 
0 I ι ι ι I I I 1 1 1 1 1 I I I I I I I I I 
0 5 10 15 20 
years after diagnosis 
these studies lead particularly to selection b ias . " ' 2 At least this problem was avoided in this 
study, which was based on all cases of diabetes mellitus diagnosed in routine general practice 
care over a period of 22 years. Patients who had moved to another area or died since the first 
diagnosis were included. Patients referred for hospital-based care were included as well, thus 
avoiding referral bias.12 Although the diagnostic criteria for diabetes mellitus have changed 
considerably during the observation period, all cases included in this study had diabetes 
mellitus according to the currently applied critena."' The definition of type of diabetes (1 or 
2) was applied consistently throughout this study group. All morbidity data have been 
collected prospectively with scrupulous care for quality and consistency of registration.13 
type 2 diabetic patients in this study were also characterised by the well-known risk factors 
such as hypertension, obesity, and lipid abnormalities, associated with insulin resistance, 
known by Reaven's syndrome X.27 The high prevalence of hypertension at the time of 
diagnosis possibly reflects the increased risk of hypertension and hypertension treatment for 
the development of diabetes.28'29 In the years following the diagnosis, hypertension was 
diagnosed in a steadily increasing number of type 2 diabetic patients, possibly reflecting the 
cardiovascular consequence of having diabetes mellitus. 
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Table 2a-3 Causes of death in type 2 diabetic patients (n = 265) and controls (n 
matched for practice, sex, age, and social class in the period 1967 - 1989. 
265), 
Myocardial infarction 
Cerebrovascular accident 
Heart failure 
Peripheral vascular disease 
Total cardiovascular deaths 
Renal failure 
Neoplasm 
Others 
Total number of deaths 
Men 
Control 
(n=112) 
7 
1 
2 
1 
11 
1 
11 
2 
25 
Type 2 
(n=112) 
12 
0 
5 
2 
19 
0 
7 
6 
32 
Women 
Control Typ( 
(n=153) (n=15 
3 
3 
5 
2 
13 7 
1 
5 
6 
25 
oa 
3 
3 
27a 
0 
4 
8 
39 
Results as absolute numbers 
ap<00l 
Some limitations of this study should be taken into consideration as well. Firstly, it has been 
demonstrated that probably 50% of all type 2 diabetic patients are not known to their GP.30 It 
is unlikely that this might be the case in this study with its special attention for cardiovascular 
morbidity and risk factors, including diabetes mellitus itself.31,32 Secondly, statistical 
significance was not reached for the differences in mortality, if distinguished for men and 
women separately, which was probably due to small absolute numbers. In the specific age 
group 45-64 years statistical significance was not reached due to shortage of follow-up. In 
the age group over 75 years it is age itself that has become the most powerful predictive 
factor. Thirdly, in theory bias might have been introduced by the exclusion of the 43 newly 
diagnosed type 2 diabetic patients with no blood glucose values on their records. The 
diagnostic criteria and the definition of the different types of diabetes in these patients could 
not be verified. Uncertainty in these respects would have damaged the study more than the 
exclusion of 14% of the potential diabetic patients. Moreover, it seems unlikely that this 
exclusion will have influenced the results essentially because this selection was based on 
diagnostic criteria and not on the course, severity or outcome of the disease. 
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Summary 
Study objective Control group characteristics as comorbidity and chronic psychosocial 
problems may play an important part in study outcomes. A primary care database was used to 
quantify the effects of varying the case mix of participants. 
Design Historical cohort study. 
Setting Data were collected from 1967-1996 in four Dutch general practices performing the 
Continuous Morbidity Registration Nijmegen. 
Patients and controls All newly diagnosed type 2 diabetic patients in the period 1967-1989 
fulfilling the WHO-cnteria (n=265); for each type 2 diabetic patient a control was matched 
for practice, sex, age, and social class; from these controls subgroups were selected based on 
the absence of different types of morbidity; these subgroups were also matched for practice, 
sex, age, and social class. 
Main results The relative risk of mortality in type 2 diabetic patients in comparison with 
various subsets of controls ranged from 1.33 (95% CI 0.97, 1.81) to 2.16 (95% CI 1.46, 
3.20). 
Conclusion Control group characteristics as comorbidity and chronic psychosocial 
problems turned out to influence the risk estimation in a cohort study. General practice data 
enhance the study of these aspects. 
Keywords primary care database, control group characteristics, type 2 diabetes mellitus, 
mortality risk 
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Introduction 
General practice networks provide databases for primary care based research. These 
databases enhance access to health related information of large groups of patients over a long 
period of time. The Nijmegen Continuous Morbidity Registration (CMR) is an example of a 
general practice database that has been in operation since 1971.1'3 From that year onwards, 
all episodes of morbidity have been recorded, in a stable population, providing valuable data 
for longitudinal research2'3 Moreover, the CMR database opens the possibility of recruiting 
patients for further study.4 Recruitment can be guided by demographic features or by features 
of a person's medical history, or both. The large number of patients in the database enables 
diversity in the choice of control groups. This paper focuses on that possibility. Controls for 
clinical studies usually are matched to index patients for demographic characteristics (sex, 
age, race, place of birth, and living, etc.) while excluding those with the clinical condition 
under study. Although the importance of the presence or absence of additional clinical 
features in controls will be generally acknowledged, few empirical data are available. 
For our case study the analysis of mortality in patients with type 2 diabetes mellitus was 
used In a previous analysis from the CMR database we compared patients with type 2 
diabetes mellitus with controls matched for sex, age, social class, and general practice, and 
we demonstrated that m a follow up up to 22 years, mortality and cardiovascular morbidity 
were increased in type 2 diabetic patients.3 For the underlying case study controls were 
recruited on the basis of (a) demographic matching (sex, age, social class, and practice of 
listing); and (b) medical history. For the latter, we were particularly interested in the effects 
on the study outcome of inclusion or exclusion of patients on the basis of illness behaviour 
(frequency of consulting the general practitioner (GP); chronic psychosocial problems) and 
comorbidity (cardiovascular morbidity and severe morbidity). The aim of the study was to 
demonstrate the potential of the database in recruiting control groups with a different case 
mix, and to quantify the effects of clinical background of controls on the outcome of the 
diabetes study. 
Patients and methods 
We studied the survival of a group of 265 type 2 diabetic patients with various sets of 
controls matched for practice, sex, age and social class.' The original study is based on the 
period 1967 - 1989. This report was based on data up to 1996. 
Practices and Data Recording 
The ongoing Continuous Morbidity Registration Nijmegen (CMR Database) started in 1967 
in four practices in and around Nijmegen.'"4 This registration aims to study epidemiological 
aspects of morbidity in general practice with special emphasis on the longitudinal aspects of 
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disease. Every episode of illness seen by or reported to the GP is registered as soon as it is 
established. In the Netherlands patients have a named GP and secondary medical care is only 
available after referral by the GP. For medical specialists it is a routine procedure to inform 
the GP about diagnosis and treatment in referred patients. All referrals and specialist reported 
diagnoses are also recorded in the registration system. To classify diagnoses the adapted E-
list is used, with a fourth digit extension to make it compatible with the ICHPPC-2 defined.5,6 
The GP also registers causes of death. A rigorous surveillance of the recorded data results in 
a database of high quality. 
The four practices have a practice population of approximately 12.000. This number has 
remained stable over the years with a turnover of less than 5% per year. For each patient the 
following information is available: sex, date of birth, date of entry in or departure from 
registration, family composition, and family social class. Social class is defined according to 
profession as well as education. 
All morbidity codes of the (adapted) E-list have been assessed for severity: a panel of 
experienced GPs has allocated to each code, after a consensus discussion, a severity score 1-4 
(1 = threatening life or important functional capacities; 2 = marked impact on health and 
functional status; 3 = limited impact on health, and functional status; 4 = not classifiable). 
Patients with type 2 diabetes mellitus 
All newly diagnosed type 2 diabetic patients between 1967 and 1989 (n = 265) including 
those who were under specialist medical care, were included in the study cohort. The 
diagnosis of all cases was reviewed using all available data from the patients' files and 
patients were only accepted for this study if the diagnostic evidence was in agreement with 
the WHO criteria.8 Patients who started insulin treatment within one year of diagnosis and 
who remained on it were regarded insulin dependent diabetes mellitus. All other patients with 
diabetes mellitus were considered type 2 diabetes mellitus, irrespective of their current 
treatment. 
Controls 
For each patient a control was selected matched for practice, sex, age (±3 months), and social 
class. Controls were selected from all patients on the practice list with exception of those 
with known diabetes at the time of diagnosis of the type 2 diabetic patient. There were no 
further exclusion criteria for controls. The year of the patients' diagnosis of type 2 diabetes 
mellitus was the start of the follow up for both patient and control Five subsets of controls 
were selected. The first subset included all controls used in the original study; the second 
subset consisted of the controls without cardiovascular risk factors (hypertension, body mass 
index > 27, hypercholesterolaemia); the third subset included the controls without 
cardiovascular morbidity (cerebrovascular accident, myocardial infarction, angina pectoris, 
heart failure, peripheral vascular disease); the fourth subset excluded controls with serious 
diseases (seventy score 1, defined as diseases that are a potential threat for life or for 
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important functional health capacities); the fifth subset excluded the controls known with 
chronic psychosocial problems. All subsets of controls were matched for practice, sex, age, 
and social class. 
Statistical Procedure 
Death rates were calculated using the cohort life table method.'' Statistical analysis was 
performed using the Mantel-Haenszel procedure and the Cox Proportional Hazard regression 
model. The data were analyzed with SAS 6.06.'° 
Results 
A total number of 265 patients were registered between 1967 and 1989 as newly diagnosed 
type 2 diabetic patients in accordance to the WHO criteria. The matching on sex, age, and 
social class and the selection of four subsets of controls (without cardiovascular risk factors; 
without cardiovascular morbidity; without diseases with seventy score 1 and without chronic 
psychosocial problems) succeeded completely. Table 2b-1 shows the clinical features at the 
start of follow up of the patients and controls. Control patients matched for sex, age, and 
social class for newly diagnosed type 2 diabetic patients had already a high prevalence of 
cardiovascular risk factors and cardiovascular morbidity at the start of follow up. 
Table 2b-l Clinical features type 2 diabetic patients and controls at start follow-up. 
Mean age (y) 
Sex (male) 
Cardiovascular morbidity 
Hypertension 
Body mass index t 27 
Hypercholesterolaemia (> 7 mmol) 
Follow up (y) 
Type 2 diabetic patients (n = 
64.7 
42.3 
24 
40 
62 
10 
10.7 
(10.2) 
(6.7) 
 265) Controls (n = 265) 
63.6 (11.1) 
42.3 
19 
23* 
34* 
3 ' 
10.1 (6.2) 
Results as percentages (except mean age, and duration diabetes/follow-up both years) 
'p<0 05 
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Within the follow up period 123 type 2 diabetic patients and 85 controls died resulting in a 
relative risk of mortality in type 2 diabetic patients of 1.59 (95% CI 1.20, 2.11), for women 
1.62 (95% CI 1.10, 2.40) and for men 1.56 (95% CI 1.03, 2.35), compared with controls 
(figure 2b-1). The 50% survival was 16 (95% CI 13, 18) compared with 24 (95% CI 17, 
unknown) years in type 2 diabetic patients and controls respectively. 
Figure 2b-l Survival of type 2 diabetic patients in general practice (n = 265) and controls 
(n = 265) in the period 1967 -1996. 
type 2 diabetic patients 
0 I I I I I I I I 1 1 1 1 1 1 1 1 1 1 1 1 I I I 1 1 I 
0 5 10 15 20 25 
years after diagnosis 
Table 2b-2 shows the influence of control group characteristics on the outcome of relative 
risk on mortality. Selecting controls without cardiovascular risk factors, cardiovascular 
morbidity or diseases with severity score 1 resulted in an increasing relative risk for mortality 
of type 2 diabetic patients (from 1.67 (95% CI 1.16, 2.40) to 2.16 (95% CI 1.46, 3.20)). 
Excluding controls with chronic psychosocial problems decreased the relative risk for type 2 
diabetic patients (1.33 95% CI 0.97, 1.81). 
Discussion 
This study showed the possibility of recruiting well-defined subgroups of control patients 
from a general practice based database. Analysis of subgroups of patients from the 
experimental group is a common phenomenon in clinical trials. However, as far as we known 
analysis with different sets of controls has not been described. 
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Table 2b-2 Mortality rates of type 2 diabetic patients compared to different sets of control 
groups 
Characteristic control group Number" Mean age (SD) % Men Risk ratio (95% CI) 
265 
171 
200 
175 
196 
63 3(12.3) 
61.3(12.8) 
60.9(12 0) 
60.1 (11.9) 
63.3(12.1) 
42.3 
48.5 
43.5 
42.9 
45.9 
1.59(1.20 
1.67(1.16 
1.73(1.23 
2.16(1.46 
1.33(0.97 
2.11) 
2.40) 
2.46) 
3.20) 
1.81) 
All controls 
Without cardiovascular risk factors 
Without cardiovascular morbidity 
Without severity score l" 
Without chronic psychosocial problems 
the number oj type 2 diabetic patients and controls are the same, matched for practice, sex. age. and social class 
Hypertension, body mass index ?27, hypercholesterolaemia 
Cerebrovascular accident, myocardial infarction, angina pectoris, heart failure, peripheral vascular disease 
Seventy score I was registered for all diseases that were a potential threat for life or important functional 
health capacities 
In this study for type 2 diabetes mellitus the choice of additional criteria for the control group 
was only of relative importance. The point estimates of the relative nsk on mortality of type 
2 diabetic patients were changing, but with large overlap in the 95% confidence intervals. 
However, the rate of reduction of life expectancy was related to the characteristics of the 
control group. On one side of the spectrum were those without serious diseases (severity 
score one), on the other side were those without chronic psychosocial problems. The findings 
with controls without chronic psychosocial problems may indicate that this is a factor to 
consider as well in the drawing of inclusion criteria for patients and controls. 
In general, controls should differ from cases under study on one essential aspect - in our 
study: type 2 diabetes mellitus - but otherwise be comparable to cases as much as possible for 
factors that have an independent influence on the study endpoints." Sex and age are 
independently related to morbidity and mortality, so matching for these factors was 
performed. But there are other factors that could have been considered as comorbidity in 
particular because of the age of patients with newly diagnosed type 2 diabetes mellitus.7'12 
Another aspect when selecting control patients from the practice lists of GPs is illness beha-
viour. People vary in their use of medical care facilities. Frequent use is among others related 
to psychosocial problems, that in turn is related to major (medical) events.13 Subjects who 
never, or hardly ever, consult a GP might be exceptionally fit, or, alternatively could be at 
risk of delayed identification of major disease. When recruiting controls from the practice 
lists of GPs, these aspects can, and must be considered. However, both patients and controls 
had been on the same practice list for a considerable time. Almost all controls had consulted 
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their GP, so the study failed to select a control group that had never been in contact with 
medical care This may point to the fact that, given the age distribution of the study group of 
type 2 diabetic patients, 'non-consulters' might not be a relevant control group only a few 
number of controls apparently did meet this cntenon However, for research in diseases with 
a high prevalence in younger age groups, it might still be important to consider this aspect 
It is concluded that comorbidity and chronic psychosocial problems in control groups play a 
part in the outcome of clinical studies The use of general practice data bases like the 
Nijmegen Continuous Morbidity Registration opens the possibility of qualifying and 
quantifying these aspects Researchers should be encouraged to explore in detail their control 
groups in relation to their findings and conclusions 
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Summary 
Background Traditionally, health and the outcomes of medical treatment have been 
measured in terms of morbidity, incidence or prevalence of disease, or even mortality. This 
disease model provides an adequate framework for acute illnesses, but for chronic diseases, 
severity and their effect on everyday functioning are paramount. For chronic diseases, 
functional health status, as a vital part of quality of life, is now recognized as an important 
outcome measure of the GP's care. 
Objective We aimed to assess the impact of type 2 diabetes mellitus on functional health 
status in Dutch general practice. 
Method We conducted a cross-sectional study of the functional health status of all patients 
with type 2 diabetes mellitus under 85 in two general practices, using the Sickness Impact 
Profile (SIP) and the COOP/WONCA charts. A control group of non-diabetic patients was 
selected, matched for practice, sex and age. 
Results In total, 127 type 2 diabetes mellitus patients and 127 controls participated in the 
study, the response being 78 and 70%, respectively. Between these groups the following 
were significantly different: the SIP subscore Physical, the SIP sum score and the 
COOP/WONCA scores for physical fitness and overall health Type 2 diabetes mellitus 
patients were 2.46 (95% CI 1.5 - 4.1) times more likely to experience functional impairment. 
Cardiovascular morbidity (odds ratio 2.5, 95% CI 1.3 - 4.7), locomotory morbidity (odds 
ratio 2.6, 95% CI 1.4 - 5.1) and diabetes itself (odds ratio 1 4, 95% CI 1.1 -1.9) were 
significantly associated with the presence of functional impairment. 
Conclusion This study demonstrates the impact of type 2 diabetes mellitus on functional 
status, particularly in relation to cardiovascular morbidity. 
Keywords General practice, health status indicators, primary health care, type 2 diabetes 
mellitus. 
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Introduction 
Type 2 diabetes (non-insulm-dependent) mellitus is one of the most complicated diseases 
managed in primary care. '" Standards were developed to establish uniform care. " Strict 
metabolic control is recommended although it is still unclear whether this prevents premature 
mortality'' and improves 'quality of life'. " However, strict metabolic control is difficult to 
achieve and even if strict metabolic control is reached and objective markers of disease are 
improved, it may adversely affect 'quality of life' as a consequence of therapeutic side-
effects." Therefore, 'quality of life' has to be an important factor in the evaluation of care. As 
one of the aspects of'quality of life', the concept of functional health status has been defined: 
the impact of disease on an individual's daily functioning.12 As functional health status 
reflects the patient's capacities rather than the activity of the disease, the instruments to assess 
functional health status are not disease specific but generic in concept. One of the difficulties 
in interpreting and understanding functional health status is the role of co-morbidity, which 
constitutes a particular problem in type 2 diabetes mellitus patients and interferes with the 
impact of diabetes itself on functional health status. 
Although many studies have described the high prevalence of complications and morbidity in 
type 2 diabetes mellitus patients, very few data concerning the impact of type 2 diabetes 
mellitus on the functional health status of patients are available. Data suggest that patients 
with diabetes experience a decrease in their 'quality of life' compared with healthy 
individuals and that functional health status decreases as complications become more 
severe.',""' The aim of this study was to assess the impact of type 2 diabetes mellitus on the 
functional health status in Dutch general practice. 
Patients and methods 
Setting 
The study was performed in two general practices (six GPs, 11,500 patients) taking part in 
the Nijmegen Monitoring Project of the Department of General Practice and Social Medicine 
of the University of Nijmegen.17 This project supervises the management of patients with 
chronic diseases in primary care. Type 2 diabetes mellitus patients are included when the 
diagnosis is in agreement with the WHO criteria.18 Patients who are treated with insulin 
within I year of diagnosis and who remain on it are regarded as type 1 diabetes mellitus 
patients (insulin-dependent); all others are considered type 2 diabetes mellitus. 
The management of diabetes mellitus in the Nijmegen Monitoring Project is based on the 
guidelines of the Dutch College of General Practitioners.^ The GP is provided with 
computer-assisted feedback on adherence to follow-up care, key clinical data on outcome of 
care and adherence to the management guidelines 
38 The Nijmegen Monitoring Project 
Patients 
All type 2 diabetes mellitus patients aged under 85 were invited to take part in the study. 
Patients were excluded when their GP had established major additional life-threatening 
morbidity or considered them unsuitable for participation on account of psychosocial 
reasons. A control group of non-diabetic patients was selected and matched for practice, sex 
and age. In all controls, blood glucose was measured. Controls with a blood glucose value in 
the diabetic range were excluded.18 
Data on co-morbidity 
The GP provided data from the records of both type 2 diabetes mellitus patients and controls 
on the presence of co-morbidity, according to the definitions of the International 
Classification of Health Problems in Primary Care (1CHPPC).2U This co-morbidity was 
categorized in seven groups: (1) cardiovascular (myocardial infarction, angina pectoris, heart 
failure, peripheral vascular disease, transient ischaemic attack, cerebrovascular accident); (2) 
hypertension (3) locomotory morbidity (rheumatoid arthritis, osteoarthritis of the hip, knee 
and lumbar spine, and back pain with radiating symptoms); (4) psychosocial problems 
(depression, anxiety, bereavement); (5) eye diseases (cataract, retinopathy); (6) cancer; and 
(7) pulmonary morbidity (asthma, COPD). 
Data on functional health status 
Two generic instruments were selected to measure functional health status: the Sickness 
Impact Profile (SIP) and the COOP/WONCA charts.21"23 No disease-specific instrument was 
included owing to the nature of this study being a comparison of type 2 diabetes mellitus 
patients and controls. For both instruments Dutch validated versions were available.23'24 
The SIP consists of 136 questions on daily functioning in relation to health and illness. These 
questions are grouped into 12 different categories. The list covers the domains of physical 
function (categories: body care/movement, mobility, ambulation), psychosocial function 
(categories: emotional behaviour, social interaction, alertness behaviour, communication) 
and 'other' functions (categories: sleep and rest, home management, work, 
recreation/pastimes and eating). The calculation of the SIP-scores are described in detail 
elsewhere.21 
The Dartmouth COOP functional status assessment charts/WONCA (COOP/WONCA) 
assess six domains of functional health: physical activities, feelings, daily activities, social 
activities, change in health and overall health. Each domain is covered by a single question to 
be answered on a five-point scale and is supported by a pictograph representing the options. 
The scores are calculated for each chart separately. 
The SIP was completed by interview and the COOP/WONCA charts were given for self-
completion. 
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Analysis 
Differences between type 2 diabetes patients, participants and nonparticipants, and controls 
with respect to socio-demographic variables, co-morbidity and clinical features were 
evaluated using the chi-square test and two-sample Mest. The main aim of the analysis was 
to compare patients and controls for each of the categones separately for their SIP and 
COOP/WONCA scores. A difference in the SIP total score of 2 is considered as clinical 
relevant." Data from a study of Jacobs with the Dutch version of the SIP (n=973) showed a 
standard deviation of 6.3 " If a similar standard deviation (SD = 6) was observed in this 
study, 142 patients and controls would be required to detect a difference of 2 on the SIP total 
score, with 80% power at the 5% significance level. Calculations for statistical significance 
for the SIP and COOP/WONCA scores used the two-sample /-test and for correlation the 
Spearman's rank lest. 
Owing to the highly skewed distribution of the SIP sum scores, a dichotomous cut-off point, 
used previously in the literature, was used to distinguish subjects with functional impairment 
(SIP sum score of 2% or higher) from subjects without functional impairment (SIP sum score 
less than 2%).' ~A Odds ratios for functional impairment were obtained by means of the 
Mantel Haenszcl procedure. 
Multiple logistic regression analysis was used to estimate the impact of diabetes and the 
combined effect of having diabetes and other co-morbidity (see section data on co-morbidity) 
on functional health. The results of the logistic regression models were summanzed using 
odds ratios with their 95% confidence intervals. 
Results 
There were 181 type 2 diabetes mellitus patients aged under 85 years in the two practices (14 
patients were over 85). Nineteen were excluded by their GP, so 162 patients were invited, of 
whom 127 participated in the study (response rate 78%) The mean age of non-participating 
type 2 diabetes mellitus patients was significantly higher (69.3 versus 64.7 years, ρ = 0.01), 
and they had significantly more cardiovascular co-morbidity (54 versus 33%, ρ = 0.02) and 
hypertension (37 versus 21%, ρ = 0.05) than participating type 2 diabetes mellitus patients. 
The mean blood glucose was significantly belter in non-participating type 2 diabetes mellitus 
patients (7 5 versus 8.6 mmol 1 ,,p = 0.02). 
A control group (;i = 181 ) was matched for practice, age and sex. Fifty-four controls declined 
participation (response rate 70%). The clinical features of all type 2 diabetes mellitus patients 
and controls arc summarized in table 3-1 Type 2 diabetes mellitus patients had a 
significantly higher body-mass index (p = 0.005), a higher prevalence of cardiovascular 
morbidity (p = 0.002) and eye diseases (p = 0 001) than controls With the sample size (n = 
127 in both groups), a power of 76% at the 5% significance level could be reached to detect a 
difference of 2 (SD - 6) on the SIP total score. For all categories of the Sickness Impact 
Profile except Emotional Behaviour, patients had higher scores than controls (table 3-2). 
40 The Ni/megen Monitoring Project 
Table 3-1 Clinical features type 2 diabetes mellitus patients and controls 
Clinical features 
Mean age (years) 
Sex men/women 
Body-mass Index men (kg/m2) 
Body-mass Index women (kg/m2) 
Cardiovascular morbidity 
Hypertension 
Locomotory morbidity 
Psychosocial morbidity 
Eye diseases 
Cancer 
Pulmonary morbidity 
Duration diabetes (years) 
Therapy: Diet / oral / insulin 
Blood glucose at the time of 
interview mmol Γ' 
Blood glucose control last yearb 
Good 
Moderate 
Poor 
Type 2 diabetes mellitus 
(n=127) 
64.7(10.2) 
35/65 
28.4 (5.9) 
29.6 (4.7) 
33 
21 
23 
11 
23 
0.8 
6 
7 3 (6 2) 
26/62/ 12 
8.6 (2 4) 
29.1 
37.6 
33.3 
Controls (n=127) 
63.6(11.1) 
35/65 
25.5(3.3)" 
27.1 (3.9)" 
17" 
15 
24 
11 
4 a 
0.8 
5 
Results are given as percentages except mean age. Body-mass Index, duration diabetes and blood glucose at the 
time of interview (standard deviation in parentheses) 
"p<00l 
Average of the fasting blood glucose measurements in the last year (n = 117. pait of the patients were not 
controlled by their GP. so no average of the blood glucose could be calculated) 
Good < 60 years s 69 mmol t'. 61-69 years <7 9mmoltl s 70 years < 8 9 mmol t' 
Moderate < 60 years 7 0-7 9 mmol l'. 61-69 years 8 0-8 9 mmol I ' - 70yems 9 0-10 9 mmol Γ ' 
Poor < 60 years ? 8 0 mmol Γ , 61-69 years ^ 9 0 mmol I . - 70 years > 11 0 mmol Γ 
For the categories of Body Care and Movement, Ambulation, Home Management, Work and 
Eating, the differences were statistically significant, resulting in a significant difference for 
the subscore 'physical' (p = 0.02) and the sumscore 'SIP total' (p = 0.003). Functional 
impairment (SIP sumscore of 2% or higher) was significantly more prevalent in the type 2 
diabetes mellitus diabetic patients than in the controls (65 versus 43%, ρ = 0.0001). Type 2 
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diabetes mellitus patients were 2.46 (95% CI 1.5 - 4.1) times more likely to experience 
functional impairment than were controls. After adjustment for cardiovascular morbidity the 
odds ratio was 2.18 (95% CI 1.3 - 3.7). 
Table 3-2 Mean Sickness Impact Profile scores" 
Dimension 1 
Physical 1 
i 
1 
! 
Psychosocial | 
1 
Other categories 
1 
1 
1 1 1 
Category 
Body Care and Movement 
Mobility 
Ambulation 
Emotional behaviour 
Social interaction 
Alertness behaviour 
Communication 
Sleep and rest 
Home management 
Work 
Recreation / pastimes 
Eating 
SIP Physical 
SIP Psychosocial 
SIP total 
Type 2 diabetes 
48 
3.5 
11.0 
33 
2.3 
2.8 
3.8 
7.1 
125 
137 
10.0 
7.1 
5.6 
2.9 
6.0 
(8.7) 
(7.1) 
(14.2) 
(8.0) 
(3.9) 
(9 8) 
(9.9) 
(12 9) 
(15.5) 
(26 7) 
(143) 
(3 8) 
(7.8) 
(5.0) 
(6.2) 
( 
3.0 
3.0 
7.3 
3.6 
1.8 
2.5 
2.2 
4.7 
7.7 
6.0 
7.7 
1 7 
3.7 
2.4 
38 
Controls 
(5.4) 
(7.1) 
(12.0) 
(9.3) 
(4.6) 
(10.3) 
(6.4) 
(10 5) 
(14.1) 
(18.2) 
(13.1) 
(3.4) 
(5.7) 
(5 6) 
(5.7) 
p-value 
0.04 
0.5 
0.02 
0.7 
0.3 
0.8 
0.1 
0.1 
0.01 
0.0007 
0.1 
0.0001 
0.02 
0.4 
0.003 
'Resulti are given as penentages ojthe total possible (Ινφιηιΐιοη (100%), standard deviation in parentheses. 
The COOP/WONCA scores for physical fitness and overall health were spread over the full 
range of the five-point score and were significantly different for patients and controls (table 
3-3) In contrast, patients and controls mostly scored 1 (excellent) and 2 (good) for the 
categories of feelings, daily activities and social activities. Most of the patients and controls 
(81 and 82%, respectively) indicated no changes of health during the preceding 2 weeks. 
Among type 2 diabetes mellitus patients a higher mean SIP sum score was associated with 
increasing duration of diabetes (p = 0.02, p-values based on Wilcoxon Rank Sums Scores) 
and the presence of cardiovascular morbidity (p = 0.05). A higher SIP sum score was not, 
however, significantly (p = 0.5) associated with poorer metabolic control. In controls, a 
higher SIP sum score was associated with increasing age {p = 0.001), the presence of 
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cardiovascular morbidity (p = 0.001), locomotory morbidity (p = 0.0005) and psychosocial 
morbidity (p = 0.02). 
Table 3-3 Distribution of scores on each of the six COOP/WONCA charts for type 2 
diabetes mellitus patients (n=l27) and controls (n = l27) 
Scores 
% of subjects in any category"1 
2 3 4 5 Mean (SD) 
Physical fitness1* 
Type 2 diabetes mellitus 
Controls 
Feelings' 
Type 2 diabetes mellitus 
Controls 
Daily activities' 
Type 2 diabetes mellitus 
Controls 
Social activities* 
Type 2 diabetes mellitus 
Controls 
Change in health ' 
Type 2 diabetes mellitus 
Controls 
Overall health' 
Type 2 diabetes mellitus 
Controls 
9 
10 
62 
62 
55 
53 
85 
84 
5 
5 
12 
20 
7 
17 
28 
24 
22 
26 
10 
10 
7 
6 
8 
12 
26 
38 
5 
10 
15 
15 
2 
3 
81 
82 
49 
49 
38 
25 
4 
4 
6 
5 
2 
2 
6 
6 
30 
17 
20 
10 
1 
0 
2 
1 
1 
1 
1 
1 
1 
2 
3.53(1.14)" 
3.07(1.11) 
1.53(0.83) 
1.55(0.83) 
1.77(1.04) 
1.76(0.97) 
1.25(0.69) 
1.26(0.70) 
2.90(0.58) 
2.91 (0.58) 
3.00 (0.94)c 
2.68(1.02) 
"Scores us percentage of subjects within any calegoiy of junctional status: I - good, through to 5 = poor. 
''p = 0.001. 
' ρ = 0.01. 
' Hairiest physical activity that could he done for at least 2 minutes, from 'vuiy heavy ' to very light '. 
' Extent of being bothered by emotional problems, from 'not at </// ' to 'extremely '. 
1Extenl of difficulties in doing usual activities, from 'no difficulty' to 'could not be done'. 
" Extent to which social activity is limited by physical and emotional health, from 'not at all ' to 'extremely '. 
'' Overall health compared with 2 weeks previously, from 'much better ' to much worse ' (3 ~ no change). 
' General health, from 'excellent ' to 'poor ' 
Multiple logistic regression analysis, with the dichotomized SIP total score as the dependent 
variable, showed that cardiovascular morbidity (odds ratio 2.5, 95% CI 1.3-4.7), diabetes 
itself (odds ratio 1.4, 95% CI 1.1-1.9) and locomotory morbidity (odds ratio 2.6, 95% CI 1.4-
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5.1) were significantly associated with the presence of functional impairment. Hypertension, 
psychosocial problems (depression, anxiety, bereavement), eye diseases (cataract, 
retinopathy) and pulmonary morbidity (asthma, COPD) were not significantly related to 
functional impairment. 
Table 3-4 shows the Spearman's rank correlation coefficients between the SIP and the 
COOP/WONCA charts. Fair (0.46-0.63) correlations were found for the COOP/WONCA 
charts Physical fitness. Daily activities and Overall health, and the SIP sum score and the SIP 
subscore Physical. The correlations between the COOP/WONCA charts Feelings and Social 
activities and the SIP subscore Psychosocial scores were moderate (0.31-0.35). Tested these 
against zero, all Spearman's rank correlation coefficients reach the significance level (p < 
0.01). 
Table 3-4 Rank correlations between dimensions of the Sickness Impact Profile and the 
categories of the COOP/WONCA charts. 
SIP 
SIP Physical 
SIP Psychosocial 
SIP Sum score 
Physical fitness 
0.63 
0 37 
0 57 
Feelings 
0 19 
0.31 
0.23 
COOP/WONCA 
Daily activities 
0 54 
0.50 
0 60 
Social activities 
0 29 
0 35 
0.31 
Overall Health 
0.46 
0.49 
0.56 
Discussion 
In this controlled study we demonstrated the impact of type 2 diabetes mellitus for the 
patient's functional health status: the physical fitness of type 2 diabetes mellitus patients was 
clearly impaired. Functional health status decreased significantly with the presence of 
comorbidity in particular cardiovascular co-morbidity and a longer duration of diabetes. 
Cardiovascular co-morbidity turns out to be not only a predominant factor m the decreased 
life expectancy of type 2 diabetes mellitus patients: it impairs the patient's functional health 
status long before as well.26 
In contrast, the scores on the psychosocial dimension were not negatively affected. Previous 
studies also suggest that the mental health of patients with diabetes did not differ 
significantly from that of patients with other chronic conditions or from the general 
population.27'28 
Although the SIP gives more detailed information, we found results in general comparable 
with the COOP/WONCA charts. First, both instruments indicate the impaired functional 
health of diabetic patients with regard to their physical fitness. However, the COOP-
WONCA chart daily activities showed no difference between type 2 diabetes mellitus 
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patients and controls, although the SIP scores on home management, work, body care and 
movement and ambulation were significantly different. Secondly, the SIP total score, which 
can be considered as a measure of overall health, was significantly different, as was the 
overall health score on the COOP-WONCA charts Thirdly, the scores on the psychosocial 
dimensions were not significantly different for either the SIP or COOP/WONCA charts. 
The SIP, a time consuming research instrument, cannot be used in daily practice. In contrast, 
large-scale implementation of the COOP/WONCA charts seems feasible in general practice, 
and scores are immediately available. However, the COOP/WONCA charts are limited by 
their nature: each dimension of functional health is reduced to one single item. Nevertheless, 
when used routinely, the COOP/WONCA charts could provide a vocabulary for patient and 
GP to discuss functional health status. 
We found four studies in which the functional health status of type 2 diabetes mellitus 
patients is compared to that of a control group.11,16 2,i21' Mitchell et cd measured the functi-
onal health of 393 type 2 diabetes mellitus diabetic patients and 486 controls using the SIP.1" 
They found that 37% of the type 2 diabetes mellitus patients experienced functional 
impairment (SIP > 2%). Our figures are higher: 64.5% of the patients and 42.5% of the 
controls had a SIP score 5 2%. However, all Mitchell's subjects were under 65 years of age 
(versus 50% in our study) and 54% of them were treated with a diet only (versus 25% in our 
study). In Mitchell's study, duration of diabetes, fasting blood glucose, hypertension. Body 
Mass Index and complications were significantly associated with the presence of functional 
impairment Stewart et al. measured functional health and well-being of 9385 adults during 
consultations with 362 physicians by means of a 20-item general health survey (the MOS 
Short-Form General Health Survey, SF-20) used by both patients and physicians.28 Patients 
with diabetes (H = 844, type 1 and type 2 diabetes mellitus) scored markedly worse on the 
domains of physical, role and social functioning. Mental health was not impaired. Ahroni et 
al used the reference group of Stewart to compare diabetic patients (>; = 577, 90% type 2 
diabetes mellitus).29 They found a larger decrease in all domains of functional status com-
pared to Stewart. Those with a history of complications associated with diabetes had signifi-
cantly more impairment than those without. Wändell el al. measured the functional health 
status of 229 diabetes mellitus diabetic patients aged 21-84 years (7% type 1, not shown 
separately), and 682 controls matched for sex and age from a standard population sample. He 
used the Swedish Health-Related Quality of Life Survey (SWEDQUAL), which instrument is 
adapted from the Medical Outcome Study (MOS). The most important independent 
predicting factors for health-related quality of life were vascular and non-vascular 
comorbidity. No significant correlations were found for duration of diabetes and HbAlc with 
the SWEDQUAL results. 
Although in our study mean SIP scores increase with poorer metabolic control, a higher SIP 
sum score was not significantly associated with poorer metabolic control. Weinberger found 
no linear relationship between dimensions of functional health status and glycosylated 
haemoglobin levels, nor did he find any association between change in glycosylated 
haemoglobin levels and change in functional health." However, three randomized 
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prospective studies showed that improved metabolic control was associated with better 
'quality of life'.8'10'30 
The evidence we found for the decreased functional health status of diabetic patients may be 
underestimated On the one hand, the study cohort was carefully diagnosed and treated for a 
long time in general practice. So, their current condition reflects their disease and not - in part 
- undertreatment or poor management. On the other hand, survival of the fittest patients over 
the years may have biased the cohort. Exclusion of frail patients by the GP may have added 
to this selection and the same is probably true for the refusal to take part: non-participants 
had more complicating co-morbidity than participants. If these less-fit patients were 
included, the scores for functional health would have indicated even more impairments. 
Our results support the inclusion of functional health status measurement in research aimed 
at the evaluation of outcomes of care in type 2 diabetes mellitus patients. In daily practice, 
treatment of type 2 diabetes mellitus patients has to be based on guidelines but will also 
largely depend on individual conditions as the role of co-morbidity and the functional health 
status. The general agreement between SIP and COOP/WONCA charts, and the latter's 
feasibility for routine practice, may suggest that these charts could provide a short, but 
systematic, orientation on functional health. 
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Summary 
In 10 computerized general practices with 26 general practitioners and 40.000 patients, all 
diabetic patients have been registered. The rate of diabetes mellitus in these practices is based 
on ordinary diagnostic activity of the GP's and not on repeated screening. The diagnoses 
have been venfied against the criteria for diabetes mellitus, adopted by the WHO, and 
analyzed separately for type 1 (insulin dependent diabetes mellitus), type 2 (non-insulin 
dependent diabetes mellitus, and impaired glucose tolerance (IGT) In 1985 the Department 
of General Practice, University of Nijmegen, The Netherlands, developed a computer-based 
monitoring system with both the aim to improve management of type 2 diabetes mellitus and 
to collect research data. The following parameters are recorded: patients socio-demographic 
data, date of diagnosis, data concerning the level of control, kind of treatment, risk-factors, 
diabetes mellitus related complications, co-morbidity, and mortality. The participating 
General Practitioner (GP) sends the data to the Department of General Practice. The 
Department of General Practice converts these data to computerized reviews. These reviews 
are discussed in monthly meetings of all participating GPs. The essentials of the monitoring 
system and some examples of feedback are discussed in this report. 
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Introduction 
Computerized registration and monitoring of diseases form an essential part of the research-
program of the Department of General Practice of the Nijmegen University. 
In 1985 a computer-based monitoring system was developed, with the aim of improvement 
of the care of patients with diabetes mellitus, especially patients with type 2 diabetes mellitus 
(non-insulin dependent) and to collect data for research. The system was introduced in 10 
general practices with a total population of 40.000 patients. These 10 practices were 
computerized and had experience in monitonng. ' '2 
Four of these practices (12.000 patients) participate in the Nijmegen Continuous Morbidity 
Registration (CMR), a project in progress since 1971. In this project, each episode of 
morbidity presented to the general practitioner (GP) is recorded, coded and computerized.3,4 
The diabetes monitoring system can be seen as an extension of these registrations, but is 
referred further as the Nijmegen Monitoring Project (NMP). Parameters to be collected 
concern; date of diagnosis, blood glucose level, other parameters concerning the level of 
control (blood pressure, height, weight, lipids), treatment modality, cardiovascular risk-
factors, co-morbidity, diabetes related complications and patient's socio-demographic data. 
In this report three issues are addressed: 
1. The description of the patients in relation to the 1985 WHO-cnteria for diabetes mellitus, 
analyzed separately for type 1 diabetes mellitus, type 2 diabetes mellitus and impaired 
glucose tolerance. 
2. Data collection and organization of the project. 
3. Some preliminary results. 
Methods and patients 
Implementation of the WHO-criteria in the NMP 
In recent decades various diagnostic criteria concerning diabetes mellitus have been used. In 
the past the diagnosis of diabetes mellitus in general practice had been based on urine testing, 
sometimes on an oral glucose tolerance test. Since about 1980, blood glucose testing has 
become standard for diagnosis and follow-up care. With the introduction of the WHO-criteria 
an international agreement on the classification and diagnostic criteria has been reached.5,6 
Later, this agreement was adopted and these recommendations have been implemented in the 
Nijmegen Monitoring Project (NMP). 
The design of the NMP took place between 1985 and 1989. In 1989, at the start of the NMP, 
records of all identified patients with diabetes mellitus were studied for the diagnostic 
criteria, date of diagnosis and co-morbidity at the time of diagnosis. 
First, the diagnosis was verified against the criteria adopted by the WHO and analyzed 
separately for diabetes mellitus and impaired glucose tolerance." In this study the diagnosis 
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of diabetes mellitus is fully established in case of one value in the abnormal range (fasting > 
6.7 and 2 hours after glucose load > 11.1 mmol) and symptoms of hyperglycaemia. In the 
asymptomatic patient with values found just above the diagnostic cut-off at least one 
additional test result with a value in the diabetic range is necessary. If such sample fails to 
confimi the diagnosis the patient was not included into the study. A patient was categorized 
as impaired glucose tolerance in case of fasting blood glucose values between 5.6 - 6.6 mmol 
and 2 hours after glucose load between 7.8 - 11.0 mmol. Since 1989 the same strict WHO-
criteria are applied for new entnes. 
Next, patients with diabetes mellitus have been subdivided into type 1 and type 2 diabetes 
mellitus. Type 1 was defined as insulin treatment within 6 months after diagnosis and still 
continued after one year. All the other patients with diabetes mellitus were defined as type 2, 
regardless of their current therapy. 
Although the monitoring system in itself draws attention to diabetes mellitus, the rate of 
diabetes mellitus in the 10 practices is based on ordinary diagnostic activity of the GP's and 
not on repeated screening. This can be illustrated in the prevalence of type 1 and type 2 
diabetes mellitus in 1990 (figure 4-1). The overall prevalence in these practices is about 
110/10.000 which is in agreement with the prevalence of diabetes mellitus in a Dutch 
General Practice, if one takes into account that one of the participating practices (N = 6.500) 
has a very young population.7 The diagnosis of type 2 diabetes mellitus is established after 
the age of 45 in 80% of all cases (figure 4-2). Figure 4-3 shows the duration of treatment of 
the type 2 diabetic patients in 1990. 
Figure 4-1 Total number of diabetics in the monitoring project, January 1990 
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Figure 4-2 Age distribution of type 2 patients at diagnoiii, January 1990 
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Structure and organization of the NMP 
At the start of the registration demographic characteristics of all diabetics, type 1 and type 2, 
have been computerized. All type 2 diabetic patients were included in the Nijmegen 
Monitoring Project. Items of the monitoring were date of diagnosis, level of control (blood 
glucose, blood pressure, weight lipids), related complications (retinopathy, nephropathy, foot 
problems), co-morbidity (cardiovascular diseases) and dropout (moved, moved to nursing 
home, mortality (table 4-1). 
Table 4-1 Items in the Nijmegen Monitoring Project 
Patient identification number 
Date of birth / sex 
Date of first diabetic symptoms 
Type of diabetes 
Date insulin therapy started, eventually stopped 
Blood glucose (fasting, 2 hours after glucose load, at random) 
HbAlc 
Cholesterol 
HDL Cholesterol 
Triglycerides 
Creatinine 
Urinary albumin excretion 
Height and weight (Body Mass Index) 
Systolic / diastolic blood pressure 
Smoking 
Retinopathy 
Cardiovascular Morbidity 
Foot complications 
Date of next visit 
Referral to specialist 
Dropout' moved, moved to nursing home, mortality 
The NMP is based on two pillars; (1) the systematic and uniform collection of data 
concerning the care and course of type 2 diabetes mellitus; (2) feedback to the GPs (figure 
4-4). 
At each encounter a check-up form is filled out. Every month the GPs send the forms to the 
Department of General Practice. The participating GPs receive a review of the data 
concerning their own practice as well as the essential data of the other practices. 
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In addition there are meetings at which the practice-reviews are discussed. These meetings 
are very important to maintain the enthusiasm and to safeguard the progression in the project. 
The follow-up has to continue over years to obtain insight in the course of type 2 diabetes 
mellitus in general practice Even 10-15 years is not sufficient to observe the majority of 
deaths in the study group except the oldest age categories, where the impact of diabetes on 
longevity is least. Also one should recall that the major impact of diabetes on the risk of 
cardiovascular disease occurs long after the onset of diabetes. 
The meetings of the participating GPs at the Department of General Practice stimulate each 
GP to maintain a uniform registration during the entire project. The feedback, the discussion 
on the subject of type 2 diabetes mellitus and the contact with other colleagues are important 
factors in achieving these objectives.10 
So far, the financial support for the project is guaranteed for 6 years (1986 - 1991). 
Figure 4-4 Diagram of the monitoring project 
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Preliminary results 
The feedback can be done on three levels. Firstly, the GP can receive a review of parameters 
of every individual patient. Parameters as duration of the diabetes, blood glucose level, blood 
pressure, weight, the last date of visiting and data of next control can be demonstrated (figure 
4-5) 
Secondly, the data are aggregated on practice level. The total number of diabetics, the 
distribution of the type of diabetes mellitus of these patients and sex-age rates is shown in a 
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review. Quality of care is illustrated with blood glucose level (figure 4-6), treatment (figure 
4-7), the number of patients that failed or came too late for follow-up care. 
Thirdly, feedback can compare variables between practices, differences in number of patients 
with diabetes mellitus, differences in the mean level of control and differences in diabetes 
mellitus related complications are reported. This will serve as a basis for discussion and will 
stimulate it is expected, an improvement of quality of care (figure 4-6 and 4-7). 
Figure 4-5 Data of one patient for the years 1983 - 1990 
Patient 59604 Glucose 
birthdate: 
sex: 
diagnosis: 
age at diagnosis: 
type: 
next control: 
14/03/28 
female 
05 1983 
55 
type 2 diabetes 
12/90 
mmol / 
Blood pressure Quetelet index 
mm Hg 
84 86 88 90 
kg/m2 
84 86 88 90 
Conclusion 
The course of diabetes mellitus varies considerably from one individual to another. 
Management of the care of diabetes mellitus requires a continuous collecting of data 
concerning this course. The computer can be helpful in collecting these data in a clear and 
structural way and in constructing a review of data concerning an individual patient. In this 
way the GP can pay attention to the course of the level of control in relationship with other 
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Figure 4-6 Ixist glucose level; per practice 1990 
l> 12nimol/l 
D 10-12 mmol/1 
D<= 10 mmol/1 
1 2 3 4 5 6 7 8 9 10 practice 
(45) (42) (35) (46) (32) (27) (60) (31) (29) (26) number of patients 
Figure 4-7 Treatment type 2; per practice 
100 
80 
60 
c 
υ 
ι-. 
ω 
α 
20 
• insulin 
• combination 
Dmono 
Ddiet 
1 2 3 4 5 6 7 8 9 10 practice 
(45) (42) (35) (46) (32) (27) (60) (31) (29) (26) number of patients 
58 Tlic Nijmegen Monitoring Project 
known risk factors. Missing data, for example the date of last check-up by a ophthalmologist, 
can be given to the GP. 
Moreover, the computer can provide a review of data concerning the care of the whole 
practice population and a comparison of these data with other practices as well as with 
external reference values. The discussion of these reviews forms the basis for the monitoring 
project, aimed to improve the outcome of care. In the monitonng project uniform data are 
collected of type 2 diabetic patients in general practice. The course of type 2 diabetes 
mellitus in general practice, the impact of the disease on health can be studied by analyzing 
these data. 
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Summary 
Objectives To assess the outcome of diabetes care in a practice based research network after 
the introduction of a audit-enhanced monitoring system. 
Study design and population An audit-enhanced monitoring system was introduced at 10 
family practices participating in the academic research network of the University of Nijmegen. 
One and seven years later, a cross-sectional analysis was performed on the outcome of care in 
all type 2 diabetes patients under treatment by their family physician. 
Outcomes measured Targets of care were: HbAlc < 8.5%, blood pressure < 150/85 mmHg. 
Targets for lipids depended on age, cardiovascular morbidity and smoking. 
Results In 1993 and 1999, 540 and 851 type 2 diabetic patients were included, representing a 
prevalence of 1.3% and 2.0%, respectively. In 1993, HbAlc > 8.5% was found in 4 1 % of the 
patients, while mean HbAlc was 8.2%. In 1999, HbAlc > 8 5% was found in 13% of the 
patients while mean HbAlc was 7.1%). (p=0.0001). Mean blood pressure and the percentage of 
patients above the target blood pressure did not change. In 1993 and 1999, mean cholesterol was 
6.2 mmol/1 and 5.4 mmol/1, respectively (p=0.0001). In 1993, 48% of the patients exceded the 
targets for lipids compared to 28% in 1999 (p=0.001). These outcomes were accompanied by an 
increased percentage of patients who had attended an annual review in the past year (73 vs 
84%). 
Conclusions Audit-enhanced monitoring in an academic family practice research setting 
achieved outcomes of diabetes care that were comparable with those reported under RCT 
conditions. 
Keywords Outcome and process assessment, monitoring, disease management, type 2 diabetes 
mellitus, primary care 
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Introduction 
Diabetes melhtus is one of the most common chronic diseases. It is associated with decreased 
life expectancy and substantial (cardiovascular) burden on health.1'2 Prevention of 
macrovascular and microvascular complications is the major treatment objective. Recent studies 
have emphasized the importance of tight metabolic control in combination with state-of-the-art 
management of other risk factors. " Against this background, guidelines for diabetes care 
recommend systematic monitoring of patients' health status, including metabolic control, 
cardiovascular nsk factors and desired outcome of care. '' ' 
However, the formulation of clinical guidelines alone is insufficient to improve actual care."' 1 2 
Strategies to reinforce the guidelines in daily practice include: monitoring the clinical condition 
of the patient over a given penod of time, feedback to the clinician about the outcome, audit of 
clinical performance, academic detailing by peers and evidence-based guidelines. ' ' 
Monitoring and feedback with systematic follow-up of relevant treatment targets enhanced a 
pro-active approach of patients, which is a key factor for successful diabetes care. 6 As large 
numbers of patients with type 2 diabetes are treated in family practice, it is important for target-
specific monitoring to fit into the overall primary care function of family practice and that it 
answers the needs, demands and expectations of patients. 
Since 1985, the Nijmegen University Department of Family Practice has been developing a 
computer-assisted practice network to study chronic diseases, the so called Nijmegen Academic 
Research Network CMR/NMP.17'18 The objectives of this network are to support care for 
patients with chronic diseases and to create a optimal setting for clinical research under family 
practice conditions. This paper analyses the outcome of diabetes care in the CMR/NMP 
Network seven years after the introduction of an audit-enhanced monitoring system.1'' 
The aims were (1) to assess the outcome of care compared to external guideline criteria and the 
results of clinical trials and (2) to assess the relations of outcome to process of care measures, 
and to patient-related and practice-related factors. 
Patients and methods 
Study population 
Data were collected at the ten family practices in the Nijmegen Academic Research Network 
CMR/NMP, with 25 family phycisians and a patient list of about 46,500 in 1999.'8 Systematic 
monitoring, feedback and audit were applied to all type 2 diabetic patients, including those who 
were under specialist medical care. Patients were included if the diagnostic evidence was in 
agreement with the WHO criteria.17'20 Patients who were treated with insulin within one year of 
diagnosis and who remained on it were considered to have type 1 diabetes mellitus. All the other 
patients were regarded as type 2, irrespective of their current treatment In addition, all reasons 
for dropping-out were recorded, including cause of death. 
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Monitoring, feedback and audit 
Since 1989, data have been collected on all type 2 diabetic patients at the time of diagnosis and 
during all the regular (3 monthly) diabetes-related control visits. In 1992, a structured annual 
review was added, based on the guidelines of the Dutch College of Family Physicians.21 
From 1992 onwards, monitoring has consisted of the assessment of: (1) compliance to 3 
monthly control and annual review; (2) glycaemic control: fasting blood glucose and HbAlc; 
(3) diabetes-related complications: retinopathy, creatinine clearance, fool problems; (4) 
cardiovascular risk factors: smoking behaviour, blood pressure, lipid profile, (5) cardiovascular 
morbidity: myocardial infarction, angina pectons, heart failure, peripheral vascular disease, 
transient ischaemic attack, cerebrovascular accident. 
Morbidity and causes of death were defined according to the definitions of the International 
Classification of Health Problems m Primary Care (ICHPPC).22 
To facilitate data collection, a computerised Research Registration System (RRS) was 
developed, and integrated into a standard Dutch electronic record system for family practice 
(Promedico, Euroned).10 
Family physicians sent the RRS data files to the University Department of Family Practice, 
where they were processed into a feedback report on process of care measures and outcome of 
care on three levels: ( 1 ) the total study population; (2) the practice population, (3) the individual 
patient. In this report process and outcome measures were compared to external criteria based 
on the guidelines of the Dutch College of Family Medicine and to the average performance at 
the other practices. Feedback items were selected in consultation with the participating 
physicians. In this way it was guaranteed that feedback corresponded with daily practice needs. 
During meetings at the University Department of Family Medicine, the feedback was presented 
and discussed. These meetings also serve to maintain uniform registration and safeguard the 
progress of the project. 
Figure 5-1 provides an example of how data are presented at the meetings. It shows the 
percentage of patients who attended their annual review in the past year 
Targets for care 
Targets for care consisted of two elements: process and outcome measures. The key marker for 
process of care was a compliance to the annual review. Key markers for desired outcome of care 
were- (1) HbAlc < 8.5%21; (2) blood pressure under 160/90 mmHg revised to 150/85 mmHg in 
199821'10; (3) lipids in reference to cardiovascular risk profile10 (a) cholesterol < 5 mmol for 
patients with cardiovascular morbidity; (b) cholesterol/HDL ratio < 5.0 in smokers without 
cardiovascular morbidity; (c) cholesterol/HDL < 6 0 in non-smokers without cardiovascular 
morbidity. Lipid lowering therapy was recommended when life expectancy was at least 5 
years."' 
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Figure 5-1 Percentage of patients with annual review in the past year (n=703) 
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Analysis 
In this study, a cross-sectional analysis was performed on the outcome of diabetes care in type 2 
diabetic patients under treatment by their family physician in 1993 and 1999. The comparison 
was based on all patients who had been under treatment for the full calendar year in 1993 and 
1999, and therefore was based on a dynamic population. Patients who died or had moved to 
another area or were admitted to a residential nursing home before the end of the year were 
excluded, as well as those who had been newly diagnosed during the year. 
Process and outcome measures are compared using chi-square, unpaired r- or Mann-Witney 
tests where appropnate. Results are expressed as means ± standard deviations or as proportions. 
Multilevel analysis was performed to assess factors that contributed to the variance in 
compliance to the annual review and the desired glycaemic level (Hbalc < 8.5%). 
Results 
In 1993, 736 type 2 diabetic patients had been included since 1989, 116 died, 68 patients had 
moved to another area and 12 patients had been admitted to a nursing home. In 1999, 1405 
patients were included, 357 died, 151 had moved to another area and 46 had gone into to a 
nursing home. Thus, the monitoring system applied to 540 in 1993 (prevalence 1.3%) and to 
851 patients in 1999 (prevalence 2.0%). 
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In 1993, 51 patients had been newly diagnosed (incidence 1.2/1000), 37 had been treated by a 
specialist (7%) and 20 did not participate (4%). The latter three categones were excluded, which 
left 432 patients in the analysis of process and outcome of care. 
In 1999, 138 patients had been newly diagnosed (incidence 3.0/1000), 88 had been were treated 
by a specialist (10%) and 31 did not participate (4%). This left 594 in the analysis of process and 
outcome of care. 
The baseline characteristics of the patients included in the analysis are shown in table 5-1. 
Table 5-1 Characteristics of type 2 diabetic patients under family phvsicum care m 1993 and 
1999 excluding newly diagnosed m the past year 
ι 1993(n=432) 1999(n=594) Ρ 
t 
Mean age (years) 68(12) 67(12) 0 34 
Male 38% 44% 0.06 
Mean duration of diabetes (years) 6.2 (3 1) 6 7 (4 8) 0.08 
Cardiovascular morbidity (%) 31 27 0.08 
I lypertension (%) 36 38 0 51 
mean Body Mass Index (kg/m2) 28.3(5 1) 292(5.1) 002 
In 1993, 73% of the patients attended their annual review versus 84% in 1999 (table 5-2). 
Increased compliance was achieved at all the practices, although there were still differences 
between practices in 1999 (figure 5-1). Univanate analysis showed that compliance to the 
annual review in 1999 was related to practice (p=0.001) but not to patient factors such as sex, 
age, duration of diabetes, therapy regimen or cardiovascular morbidity. The patients who did not 
attend their annual review had a statistically significantly higher fasting blood glucose level than 
the patients who did comply: 8 9 mmol/l and 8.2 mmol, respectively (p=0.03). In 1993, 59% of 
the patients had visited an ophthalmologist in the past two years versus 80% in 1999 (p=0.001). 
In 1993, HbAlc was measured in 51% of the patients and reached a mean of 8.2% In 1999, the 
compliance to measure HbAlc improved to 82%, with a mean HbAlc level of 7 1% (p= 0.0001, 
table 5-3). The percentages of patients with an HbAlc level of > 8 5% decreased from 4 1 % to 
13% (p=0.001). These outcomes were associated with changes in treatment (p=0.001): decrease 
in diet only (22% in 1993 compared to 13% in 1999) and in oral hypoglycacmic monotherapy 
(45% in 1993 vs 37% in 1999), increase in combination therapy with two or more oral 
hypoglycaemic agents (22% in 1993 vs 31% in 1999) and increase in insulin therapy (11 in 
1993 vs 19% in 1999) 
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Table 5-2 Process of care for type 2 diabetic patients under family physician care (1993 vs 
1999) 
1993(n=432) 1999(n=594) 
% compliance to criterion % compliance to criterion 
(range between practices) (range between practices) 
Any diabetic control m past year ! 97 (89-100) 96 (91-100) 
Annual review in past year I 73 (34-90) 84 (64-100) 
Visit to ophthalmologist in past two years 59 (40 - 79) 80 (60 - 94) 
Univariate analysis showed that poor glycaemic control (HbAlc > 8.5%) in 1999 was related to 
the therapy regimen (p=0.001), but not to sex, age, duration of diabetes, cardiovascular 
morbidity or practice. The glycaemic control in patients treated with combination therapy or 
insulin was poorer than in patients with diet only or oral hypoglycaemic monotherapy. 
Mean systolic and diastolic blood pressure and the percentage of patients with a systolic blood 
pressure of over 150 or a diastolic blood pressure of over 85 did not change between 1993 and 
1999 (table 5-3). 
In 1999, mean cholesterol level (6.2 vs 5.4 mmol/1, p= 0/0001) and mean triglycerides (2.54 vs 
2.07, p=().0003) were statistically significantly lower than in 1993 (table 5-3). In 1993 and 1999, 
data regarding which patients could be considered for lipid lowering therapy were available in 
63% and 82%, respectively. In 1993, 48% of the patients had not reached the targets for lipids 
compared to 28% in 1999 (p=0.001). 
Multilevel analysis showed that performed annual review (process) was related to practice 
(Intraclass Correlation Coefficient = 0.29), but not to patient factors. A positive outcome 
(defined as reaching the glycaemia target level: HbAlc < 8.5%) was not related to practice 
(Intraclass Correlation Coefficient = 0.003), but it was related to treatment modality which 
explained 11% of the variance. 
Discussion 
During seven years of structured audit-enhanced monitoring of type 2 diabetic patients in an 
Academic Family Practice Research Network outcome of care improved: especially the mean 
Hb A1 c of 7.1 % can be seen as an endpoint of good quality of care. The number of patients 
treated according to the Dutch family practice guidelines (process of care) also increased.10,21 
Our data were collected during normal daily care (effectiveness) and the findings come close to 
the outcome of care under trial conditions (efficacy).21 In the UKPDS, all newly diagnosed 
patients, over a period of 10 years the median HbAlc level in the intensive blood-glucose 
Table 5-3 Outcomes of care for type 2 diabetic patients under family physician care (1993 versus 1999) 
Mean fasting glucose (mmol/1) 
Mean HbAlc (percentage) 
HbAlc < 7% 
7 - 8.5% 
Ì 8.5% 
Mean systolic blood pressure (mmHg) 
Systolic blood pressure > 150 mmHg 
Mean diastolic blood pressure (mmHg) 
diastolic blood pressure > 85 mmHg 
Mean cholesterol (mmol/1) 
Mean HDL (mmol/1) 
1993(n=432) missing (%) 1999 (n= 594) missing (%) p = 
8.6(2.9) 
8 3 (2 2) 
30% 
29% 
4 1 % 
150(20) 
46% 
84(12) 
34% 
6.2(1.3) 
1.2(0.6) 
Mean triglyceride 2.6(1.5) 
Cardiovascular morbidity cholesterol > 5 mmol/1 31 % 
No cardiovascular morbidity and smokers Cholesterol/HDL > 5.0 4 % 
No cardiovascular morbidity and no smokers. Cholesterol/HDL > 6.0 13 % 
3 
50 
Ì 
50 
J 
28 
28 
31 
62 
58 
Ì 
37 
8.3 (2.6) 
7.1(1.5) 
52% 
35% 
13% 
150(20) 
46% 
82(9) 
34% 
5.4(11) 
1.2(0 4) 
2.1(13) 
17% 
5% 
6% 
4 
18 
1 
18 
J 
17 
17 
17 
23 
23 
Ì 
18 
0.07 
0.0001 
Ì 
0.001 
J 
0.90 
0.97 
0.06 
0.97 
0.0001 
0 59 
0 0001 
Ì 
0.001 
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policy group reached a comparable level of 7.0%.3 In hypertensive type 2 diabetic patients, 
recruited to the UKPDS, a mean blood pressure of 144/82 mmHg was achieved in the group 
assigned to tight blood pressure control, compared to 150/82 mmHg in our study. However, our 
study population did not consist exclusively of hypertensive patients. Compared to the 4S study, 
our cholesterol results were poorer (mean 5.7 vs 4.9 mmol), but the same mean HDL cholesterol 
level ( 1.2 mmol) was reached. Thus, the outcome in our study come close to that achieved 
under trial conditions. When we regarded patients without outcome data as poorly controlled 
(worst case scenario), then 28% had an HbAlc > 8.5%, 65% had a systolic blood pressure of 
over 150, 44% had a diastolic blood pressure of over 85 and 42% did not reach the target level 
for lipid control. 
Our outcome was reached through enhanced compliance to guidelines. Consequently, the 
outcome in 1999 was based on a larger percentage of the available patients. As the 
monitoring system contained a dynamic group of patients, the study groups in 1993 and 1999 
were not identical. Theoretically, improvement in outcome could have been reached by 
including more easily manageable patients. However, no patients-related factors such as sex, 
age, duration of diabetes, treatment modality or cardiovascular morbidity were related to 
compliance to annual review. The higher fasting blood glucose level in patients non-
compliant to annual review was probably a reflection of undertreatment rather than more 
severe illness status. Therefor, we are confident that the findings reflect improved overall 
diabetes care. 
The data on process measures in this study compare favourably to the multi-practice audits of 
diabetes care in the United Kingdom.2"I'2S The high prevalence rate of 2 0% (exclusively type 2 
diabetes patients) supports the validity of our data.22"26 In our patients, 96% had been seen at 
least once during the past year. In the studies by Khunti and Bennett, both large audits, this was 
85%.24 ""' Also the mean annual compliance to the measurement of HbAlc and blood pressure of 
almost 85% was high. Particularly compliance to the control of lipids242'''27 and fundoscopy 
was better in our study. 
In two longitudinal studies that used an organised care system with feed-back to the 
participating family physicians, compliance rates of up to 75% with respect to process measures 
were reported. 
The outcomes of this study were achieved in an Academic Family Practice Research Network, 
with specific facilities for the pro-active supervision of patients with chronic diseases. These 
results cannot - and should not - be generalised to 'routine' family practice Monitoring and 
feedback in routine family practice are in themselves insufficient to improve the quality of 
care.1' Care assessment should preferably lake a more comprehensive approach, in which 
evidence-based goals for care are formulated, care is improved to reach these goals and care is 
measured to sec whether these goals have been achieved ' ' Our academic network provides this 
comprehensive approach, while the routine of holding practice meetings can be seen as 
'academic detailing'. 
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Two major conclusions can be drawn from this study: 
(1) Audit-enhanced monitoring in a family practice research setting achieved outcomes of 
diabetes care that were comparable with those reported in RCTs. Therefore, it is possible for the 
management of diabetes in family practice to be efficacious and this should encourage greater 
investment in routine family practice to bridge the gap between efficacy and effectiveness. As 
the investment and support of our academic network was fairly modest, this approach will 
probably be cost-effective.31 
(2) There remained important differences in achieved process measures between the academic 
family practices. The favourable outcome of diabetes care the network should not hide the fact 
that the outcome of treatment was unsatisfactory in a substantial number of patients. This 
signals the need to develop further implementation strategies. 
This study demonstrated that it is possible to achieve a high quality of diabetes care in family 
practice. This provides a transparant approach to diabetes care and a solid frame work on which 
to base overall family practice. Audit-enhanced monitonng should be implemented as part of a 
quality improvement system in routine family practice, because this is where the most patients 
with type 2 diabetes mellitus will derive the greatest benefit. 
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Summary 
Background Stnct glycaemic control in type 2 diabetic patients is recommended in a number 
of treatment protocols. However, although better glycaemic control prevents or postpones 
chronic diabetic complications, it remains uncertain how this affects quality of life on the short 
and long term. 
Aim To study the impact of insulin therapy on glycaemic control and quality of life in type 2 
diabetic patients with secondary failure on maximal oral medication. 
Method Patients were selected from 10 general practices, participating in the Nijmegen 
Monitoring Project. Patients, poorly controlled on maximal oral therapy, were randomly 
allocated, stratified to age and gender, to insulin therapy in two different schedules: after a 12 
weeks penod with enhanced compliance to diet and oral therapy or as soon as secondary failure 
was established. Patients were referred lo a diabetologist to start insulin therapy and were 
referred back to their General Practitioner as soon as glycaemic control was stable. We assessed 
fasting blood glucose, HbAlc, functional health and quality of life (Sickness Impact Profile, 
COOP/WONCA Charts, Diabetes Symptom Checklist) at baseline, after the patient was referred 
back to the GP and 9 months later. Two separate sets of analyses were performed: a longitudinal 
analysis of those patients converted to insulin therapy and a comparison of 12 weeks outcomes 
between the two randomisation groups 
Results Of the 38 included patients three patients dropped out and seven patients were not 
switched over to insulin therapy. In patients starting insulin therapy mean HbAlc and fasting 
blood glucose level decreased from 9.5% to 7.6% and from 12.0 mmol to 8.4 mmol respectively 
(p < 0.001). The better control was accompanied by a decrease in hyperglycacmic complaints 
(p=0.01). No increase in hypoglycaemic complaints was found. There were no statistically 
significant changes in quality of life parameters. 
After 12 weeks, patients directly referred to insulin therapy showed a statistically significant 
improvement in HbAlc and fasting glucose level in contrast to patients with enhanced 
compliance. Quality of Life scores did not differ statistically significant. 
Conclusion Insulin therapy in poorly controlled type 2 diabetic patients from general practice 
resulted in a clinical significant improvement of glycaemic control, accompanied by a reduction 
of hyperglycacmic complaints without a increase in hypoglycaemic complaints or an adverse 
influence on Quality of Life. 
Keywords Insulin therapy, poorly controlled, type 2 diabetes. Quality of Life, General Practice 
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Introduction 
The life expectancy and quality of life of type 2 diabetic patients is reduced by the long term 
complications of this chronic disease, in particular cardiovascular morbidity.1,2 The United 
Kingdom Prospective Diabetes Study showed that light blood glucose control in newly 
diagnosed type 2 diabetes patients resulted in a 25 % risk reduction in microvascular endpoints 
but not in a statistically significant reduction in cardiovascular morbidity and mortality.3 
Nevertheless, many studies in type 2 diabetes showed a positive relation between a higher blood 
glucose level and higher mortality, suggesting that lower indices of blood glucose control are 
associated with longer life As a consequence strict glycaemic control is recommended in a 
number of treatment protocols.6'7'8 
However, although better glycaemic control prevents or postpones chronic diabetic 
complications, it remains uncertain how this affects quality of life on the short and long term. In 
some studies well controlled type 2 diabetic patients experience fewer symptoms and better 
quality of life compared to less controlled patients.''Iü In other studies better glycaemic control 
was not associated with a better quality of life. 
These results seem to reflect the expenence from daily practice that hyperglycaemia can give 
rise to symptoms, but that measures to reach strict glycaemic control may interfere with patients' 
life style and may cause side effects. Both elements may be present in case of poor metabolic 
control in spite of maximum oral medication. When in this situation insulin is considered, 
patients and even general practitioners often hesitate l",1,•l6 Patients are afraid of the daily 
insulin injections, self monitoring of blood glucose and hypoglycaemic episodes. General 
Practitioners mostly do not feel familiar with insulin therapy and do not have access to a 
specialist diabetic nurse to arrange necessary education.16 So in case of insulin therapy patients 
have to be referred, which cause discomfort especially for the older patient. This is the 
circumstantial evidence that the expected negative impact of insulin therapy on daily 
functioning and quality of life may cause delay by patient and general practitioner to start a 
therapy with proven benefit on clinical outcomes.' 
Therefore we studied the impact of insulin therapy on daily functioning and quality of life in 
type 2 diabetic patients with secondary failure on maximal oral medication. Patients were 
referred to a diabetologist for initiation of insulin therapy and were referred back to their 
General Practitioner as soon as glycaemic control is stable. A second aim was to assess the 
effect on glycaemic control and quality of life of a strict control regimen by the GP with 
enhanced compliance to diet and oral therapy before starting insulin therapy. 
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Patients and methods 
Setting and study population 
Patients were selected from the Nijmegen Monitonng Project (NMP) In this project a 
longitudinal registration of chronic diseases in 10 general practice is in progress since 1985. The 
extensive design and purpose of the Nijmegen Monitonng Project were presented earlier.17,18 
The management of diabetes mellitus in the NMP is based on the guidelines of the Dutch 
College of General Practitioners.1'' 
This study included type 2 diabetic patients with secondary failure: poor glycaemic control in 
spite of maximum oral medication. Poor glycaemic control was defined as age dependent too 
high fasting blood glucose levels on average over the last 12 months (< 60 years: s 8.0 mmol, 
60-70 years: >9.0 mmol, > 70 years > 11.0 mmol20) or a HbAlc level · 8.0%. Maximum oral 
medication was defined as the use of sulphonyl-ureum and biguamde in maximal oral dosages. 
The study was approved by the scientific and ethical committee of the Nijmegen University. All 
patients were asked written informed consent. 
Study design 
To evaluate the possible bias, introduced through the specific setting and high attention related 
to the start of insulin therapy (among others referral to a diabetologist and diabetic nurse), 
patients were randomly allocated, stratified to age (under and over 70 years) and gender, to 
insulin therapy in two different schedules (table 6-1 ): 
(1) study group A: insulin was started if poor control remained after a 12 weeks penod, wherein 
a final attempt was undertaken by the GP to enhance compliance to diet and oral therapy; during 
this penod patients were seen monthly by the GP and dietician; 
(2) study group B: insulin therapy was started after secondary failure was established. 
End points were glycaemic control and functional health. These end points were compared in 
two separate sets of analyses. Firstly a longitudinal analysis of all patients converted to insulin 
therapy (group A and group B) over a penod of nine months. Secondly a comparison of 12 
weeks outcomes between patients randomised to continuing oral medication with enhanced 
compliance, patients randomised to insulin therapy (group A versus group B) 
Intervention: insulin therapy 
Patients were switched over to insulin therapy in a shared care model. A diabetologist initialized 
insulin therapy in an out patient department setting After 12 weeks, or as soon as glycaemic 
control was sufficiently improved and stable, patients were referred back to their GP. 
At the outpatient department all patients were first visiting a diabetes specialist nurse. The 
diabetes nurse provided information and education which included general knowledge of 
diabetes and self monitonng of blood glucose Next all oral hypoglycaemic medication was 
slopped and two daily injections, before breakfast and dinner, of a combination of short acting 
Table 6-1 Sliich design 
Time in weeks 
Group A* 
Intervention 
Standard medical examination by GP ς 
Quality ol life/Functional health assessment ^  * · 
HbAlc, lipid profile ";';" · 
0 12 24 40 52 
enhanced compliance stai ι insulin referred back to GP end of study 
• • A 
Group Bb 
Intervention start insulin referred back to GP end of study 
Standard medical examination by G P c · • • 
Quality oi life/Functional health assessmentd · • • 
HbAlc, lipid profile · • A 
" stiuh gioup A insulin was stai ted ι) pool contiol lemamed afiei a 12 weeks penod wheiem a final attempi was undei taken b\ the GP to enhance compliance to diet and oial 
thei ap\ 
' stud\ gioup Β insulin theiap) was stai ted as soon as secondali falline was conjiimed 
r
 accoidmgtoa standaid pi otocol including physical examination medical histoi ) 
'' the Sickness Impact Piofile (SIP) the COOP/ttONCA cliails the Diabetes Symptom Checklist (DSC 2) 
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and intermediate acting insulin (Mixtard 30· 30% dissolved insulin and 70% isophane insulin, 
Novo Nordisk A/S Denmark) was started. 
Physical examination, medical history, laboratory investigation 
All patients were examined by the general practitioner according lo a standard protocol 
including physical examination, medical history, blood samples at baseline, at referral for 
insulin therapy (for half of the patients this was also their baseline measurement, see table 6-1), 
after the patient was referred back and 6 months later. For medical history a standardized 
questionnaire was used containing questions about cardiovascular riskfactors, cardiovascular 
morbidity, diabetes complications and comorbidity. A blood sample was analyzed for HbAlc, 
total serum cholesterol, HDL-cholesterol, triglycerides and serum creatinine. 
Quality of life 
'Quality of Life' was operationahsed as functional health status: the impact of a disease on an 
individual's daily functioning21 and measured with two questionnaires, the Sickness Impact 
Profile (SIP) and the COOP/WONCA charts.22 23'24 As the intervention was to achieve improved 
glycaemic control, we expected a decrease of hyperglycaemic complaints and eventually a 
increase in hypoglycaemic complaints. Therefor also a disease specific instrument, the Diabetes 
Symptom Checklist (DSC-2), was used.2 For all instruments Dutch validated versions were 
available.24'25,20 The SIP consists of 136 questions on daily functioning in relation to health and 
illness. These questions are grouped into 12 different categories. The calculation of the SIP-
scores are described in detail elsewhere.22 
The Dartmouth COOP functional status assessment charls/WONCA (COOP/WONCA) assess 
six domains of functional health: physical activities, feelings, daily activities, social activities, 
change in health and overall health. Each domain is covered by a single question supported by a 
pictograph representing the options. 4 
The Diabetes Symptom Checklist (DSC-2) has been specially developed to assess the frequency 
and seventy of diabetes mellitus related symptoms in type 2 diabetes. It includes 34 questions 
covering six symptom categones: hyperglycaemic; hypoglycaemic; cardiovascular; 
Polyneuropathie sensory and pain; psychological fatigue and cognitive distress and 
ophthalmological. The calculation of the DSC-2 scores are desenbed in detail elsewhere.^ The 
SIP was completed by interview, the COOP/WONCA charts and DSC-2 were given for self-
completion. 
Statistical analyses 
Baseline clinical charactenstics in patients who did or did not switched over to insulin therapy 
were compared with chi-square, unpaired T-lest (2-tailed) or Mann Whitney U-test To compare 
differences in baseline, follow-up (referred back to GP) and final results with respect to clinical 
charactenstics and Quality of Life questionnaires repeated measurement analysis was used. To 
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compare differences in baseline and final results paired analysis was accomplished using the 
Wilcoxon scores or T-tests when appropriate. The SAS (Statistical Analysis System, version 
6 12, SAS Institute, Cary, NC) was used for data analysis. 
Results 
In thirty-eight patients secondary failure was established. These patients were randomized, 
according to age and gender: 18 patients started with a 12 weeks period of enhanced compliance 
to diet and oral medication (group A) and 20 patients were referred directly for insulin therapy 
(group B). 
Three of these patients dropped out: one patient revoked her initially given informed consent 
and in two patients the protocol was no longer followed after referral to a diabetologist. As a 
consequence, from both last patients no follow-up data were available. So, there remain 35 
patients: 17 patients in group A and 18 patients in group Β 
Table 6-2 Baseline characteristics 
Man / woman 
Mean age 
Duration ol diabetes (years) 
IIbAlc(%) 
Patients with HbAlc > 8% 
Fasting glucose level (mmol) 
Body Mass Index (kg/nr) 
Waist to Hip ratio Man 
Waist to Hip ratio Woman 
C urrent smokers 
Comorhulih 
Hypertension 
Cardiovascular morbidity 
Locomotory morbidity 
Pulmonary morbidity 
Psychosocial morbidity 
switched over to 
insulin (n=28) 
II (39%)/ 17 (61%) 
60 3(11 5) 
8.7(3.1) 
9 4 ( 2 2) 
18 (64%) 
117(2 1) 
28 9 (6.2) 
0 95 
0 94 
8 (29%) 
6(21%) 
9(32%) 
6(21%) 
5 ( 18%) 
3(11%) 
not switched over to 
insulin (n=7) 
4 (57%) / 3 (43%) 
59 9 (9.7) 
7.5 (5.0) 
8 4(2.2) 
3 (43%) 
8 9(1.4) 
37.2 (9.6) 
1.03 
0 88 
1 (14%) 
3 (43%) 
1 (14%) 
1 (14%) 
0 
1 (14%) 
Ρ 
0.43 
0.93 
0.42 
0.32 
0.40 
0.002 
0.008 
0.13 
0 36 
0 6 4 
0 34 
0.64 
1.00 
0.55 
1.00 
Seven patients were not switched over to insulin therapy: ( 1 ) five patients from group A were no 
longer poorly controlled after 12 weeks of enhanced compliance; (2) in two patients of group Β 
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the diabetologist did not start insulin therapy as a consequence of markedly improved glycaemic 
control after education by the diabetes nurse and starting self monitoring of blood glucose by the 
patient. The rate of not starting insulin therapy (29% vs 11%) was not statistically different 
between the two study groups. Patients not switched over to insulin had at baseline a statistically 
significant lower fasting glucose level (p=0.002) and a higher Body Mass Index (p=0.008) 
compared to patients that were started insulin therapy (table 6-2). 
Table 6-3 Changes m clinical features type 2 diabetic patients, with poorly glycaemic control 
in spite of maximum oral medication, switched over for insulin therapy 
HbAlc (%) 
Fasting blood glucose (mmol) 
Cholesterol (mmol) 
HDL cholesterol (mmol) 
Triglycerides (mmol) 
Systolic (mmHg) 
Diastolic (mmHg) 
Body Mass Index (kg/m2) 
Weight (kg) 
At referral for 
insulin th 
9.5 
12 0 
6.2 
10 
4.2 
148 
84 
28.6 
erapy 
(2 2) 
(2 1) 
(1.6) 
(0 3) 
(6.6) 
(21) 
(12) 
(6 3) 
79.1(20 2) 
Referred back 
82 
9.0 
6.1 
1.3 
2.5 
143 
80 
29 2 
toGP 
(19) 
(2 8) 
(1.2) 
(0.5) 
(2.9) 
(24) 
(ID 
(6 0) 
80.6(19 2) 
Six months 
control by GP 
7.6 
8.4 
5.7 
1 1 
32 
146 
78 
29 8 
(1.9) 
(2.1) 
(15) 
(0.3) 
(3.5) 
(26) 
(11) 
(5 9) 
82 5(18.6) 
Ρ 
< 0.001 
< 0.001 
0.14 
0.001 
0.18 
0.57 
0.02 
< 0.001 
0.001 
Twenty-eight patients switched over to insulin therapy. The baseline characteristics of these 
patients are showed in table 6-2. One patient on insulin therapy was withdrawn by the GP from 
further follow-up, after an attempted suicide in the period he was under control of the 
diabetologist. 
In the remaining 27 patients mean HbAlc and fasting blood glucose level decreased statistically 
significant from 9.5% to 7.6% and from 12 0 mmol to 8 4 mmol respectively (p < 0.001, table 
6-3). In 19 patients HbAlc decreased > 1%, in only three patients the HbAlc value at the end of 
study was higher than at baseline (+0.4 - +1.5%). The better control was accompanied by a 
statistically significant decrease in hyperglycaemic complaints (p= 0.01), especially obtained in 
the first 12 weeks of insulin therapy (table 6-4) No hypoglycaemic event occurred that required 
professional medical intervention and no increase in hypoglycaemic complaints was found. The 
mean weight increased 3.4 kg (p=0.001), resulting in a mean increase of the Body Mass Index 
of 1.3 kg/m2 (p < 0.001). Blood pressure and lipid profiles showed a trend to improvement 
(table 6-3). Diastolic blood pressure (from 84 mmHg to 78 mmHg, p=0.02), and HDL 
Cholesterol (from 1.0 mmol to 1.1 mmol, p=0.001) improved statistically significant. 
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Although the SIP total score showed a small decrease, none of the subdimensions of the SIP 
(data not showed), neither the Physical or Psychosocial subscores, showed a significant change 
(table 6-4). Functional health expressed with the COOP/WONCA charts showed a similar 
pattern, with exception of the dimension change in health (p=0.006) showing an improvement. 
Differences in HbAIc levels and Quality of Life scores between baseline and the end of study in 
patients from group A and B, showed no statistically significant differences 
Table 6-4 Changes in quality of life scores of type 2 diabetic patients, with poorly glycaemic 
control in spite of maximum oral medication, switched over for insulin therapy 
Sickness Impact Profile " 
Physical 
Psychosocial 
Total 
COOP/WONCA charts " 
Physical fitness 
Feelings 
Daily activities 
Social activities 
Change in health 
Overall health 
DSC-2 ' 
Hyperglycaemic complaints 
Hypoglycaemic complaints 
Sum DSC-2 total 
At referral for 
insulin therapy 
4 6(6.3) 
4 4(6.8) 
6 2 (6 4) 
3.4(1 1) 
1.6(0 8) 
2.0(1 1) 
1.4(0 6) 
2.9(0 7) 
3 1 (0 9) 
3 8(2.9) 
1.1(1.7) 
2 3(1.6) 
Referred 
back to GP 
4.5 (7.5) 
4 3 (9 9) 
6.1 (9.2) 
3 4 ( 1 3 ) 
1.6(0.9) 
1.8(1.2) 
1.4(1.0) 
2.2(0.9) 
2.6(0.9) 
2 0(2.7) 
0.8(1.5) 
14(1.5) 
Six months 
control by GP 
4 8(9 3) 
2 9 (5 2) 
5.5 (8.2) 
3 5(1.2) 
1 6 (0 7) 
1.8(1.2) 
1 4 (0 9) 
2.6 (0.8) 
3 0 ( 0 8) 
2 6 ( 2 5) 
0.7(1.3) 
1 7 ( 1 4 ) 
Ρ 
0.9 
0 7 
0.9 
0.9 
1.0 
0.8 
0.9 
0.006 
0.07 
0.01 
0.40 
0.02 
" Α Ιιιφα score ι eflec ts worse functional health 
' Se m c lange from I = 'nol limited at all' to 5 = 'severel) limned' 
The t hange in health thai 11 anges from 1= 'much betlei ' to 5 = 'much woise' 
A highei scoi e refleils more compia mis 
The effects on glycaemic control and quality of life of 12 weeks with enhanced compliance to 
oral medication and diet (group A) compared to direct switching to insulin therapy (group B) are 
presented in table 6-5. At baseline there were no statistically significant differences with respect 
to any of the charactenstics showed in table 6-2 and to the scores for Quality of life between 
both groups. The differences for Body Mass Index (p=0.04) and scores on hypoglycaemic 
complaints (p=0.03 ) might regard as non-significant as we have made multiple compansons, in 
which case probabilities are significant at the 1% level Patients directly referred for insulin 
therapy showed a clinically and statistically significant improvement in HbAIc and fasting 
glucose level after 12 weeks insulin therapy. This was not the case in patients after 12 with 
Table 6-5 Changes in glycaemic control and Quality of Life parameters" after 12 weeks with enhanced compliance compared or insulin therapy. 
Group A 
12 weeks with enhanced compliance (n=17) 
HbAlc(%) 
fasting blood glucose (mmol) 
Patients switched to insulin 
SIP 
Physical 
Psychosocial 
Total 
DSC-2 
Hyper 
Fatigue 
Cognitive 
Hypo 
Total 
I 
start (TO) 
8.7(1.7) 
10.3(2.3) 
3.4(5.3) 
3.5 (4.9) 
5.2(6.3) 
4.0 (3.4) 
2.9 (2.9) 
1.6(2.5) 
0.5(1.7) 
2.1 (1.4) 
after 12 weeks (Tl) 
9.0 (2.4) 
10.7 (2.6) 
12(71%) 
4.4 (4.9) 
3.0 (3.8) 
6.0 (4.7) 
1.6(2.5) 
3.2(3.0) 
1.5(2.4) 
0.5(1.4) 
1.9(1.4) 
Group Β 
directly referred for insulin therapy (n=18) 
start (TO) 
9.7(2.6) 
11.9(2.0) 
4.5 (6.6) 
6.7(9.8) 
6.8 (7.0) 
4.2(3.3) 
3.9(3.7) 
1.7(2.2) 
1.5(1.7)" 
2.3(1.7) 
after 12 weeks (Tl) 
8.0(1.9) 
8.6(3.0) 
16(89%) 
5.0 (8.0) 
7.0(13.0) 
7.6 (10.2 
2.2 (2.4) 
3.1 (2.8) 
1.7(2.3) 
1.5(1.7) 
1.7(1.8) 
Ρ 
difference Tl-TO 
0.002 
< 0.001 
0.21 
0.24 
0.63 
0.44 
0.49 
0.81 
0.69 
0.67 
0.96 
" data ofCOOP/MONCA charts not showed, al baseline and after 12 weeks no differences between the two study groups 
hypoglycaemic complaints were at baseline statistically different between group A and group Β (p=0.04) 
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enhanced compliance. The change in scores on SIP, COOP/WONCA (not shown) or DSC-2 
were not statistically significant different between the both study groups. 
Discussion 
This study showed that insulin therapy in poorly controlled type 2 diabetic patients from general 
practice resulted in a clinical significant improvement of glycaemic control, accompanied by a 
statistically significant reduction of hyperglycaemic complaints without an increase in 
hypoglycaemic complaints. On the short term (9 months) insulin therapy had no adverse 
influence on Quality of Life. Better glycaemic control was maintained and even further 
improved, after the patient was referred back to the GP. 
As functional health will depend largely from existing comorbidity,227 it can be argued that 
improvement of functional health, by better glycaemic control, was not to be expected. 
Moreover, the standard deviations for most items of the Quality of Life instruments were large 
as a consequence of the small number of patients and the specific properties of such instruments. 
So, change in scores in our study will not easily reach statistical significance as is the case in the 
trend to improvement found in the psychosocial dimension and total scores of the SIP. 
A problem in studies comparing the effect of insulin therapy is that, since they can not be 
double-blind, bias may be introduced through the attitude of those prescribing the treatment as 
well as the specific setting with a high attention to therapy consequences (among others referral 
to a specialist nurse). Particularly, this may be true for quality of life aspects. To evaluate this 
eventual bias we randomized patients in two different schedules for insulin therapy. As we 
found no differences on Quality of Life scores between patients from group A and B, neither 
after 12 weeks and nor at the end of study, the effect on Quality of Life scores seems not 
influenced by the penod of enhanced compliance by GP in group A. Nevertheless, after 12 
weeks in 5 of the 17 patients in group A insulin therapy could be postponed and hyperglycaemic 
complaints improved in a similar way as in patients switched to insulin therapy. 
There are only few studies concerning the effect of insulin therapy on quality of life in patients 
failing to respond adequately to oral therapy. 
These studies showed that initiation of insulin therapy improves glycaemic control effectively 
and, although insulin therapy is expenenced as more demanding, insulin therapy does not 
adversely influence quality of life.12'1"'28'29 Moreover, these studies show that quality of life 
scores are not associated to HbAl levels or the achievement of an objectively better 
control. " 
Our study in general practice underlines that insulin therapy in type 2 diabetic patients with 
secondary failure results in an improvement of glycaemic control without adverse influences on 
quality of life. So, the reluctance to start insulin therapy by some General Practitioners and 
patients may be based on a prejudice towards presumed consequences of the treatment, rather 
than on actual effects '"' On the other hand, the case reports of diabetologists pointing at marked 
improvement in sense of well being after starting insulin is not supported by our study neither 
by literature. 
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Summary 
Objective To evaluate the Micral test, a semiquantitative dipstick test, in a general practice 
setting. 
Patients and methods 317 type 2 diabetic patients completed a screening for 
microalbuminuria by means of the Micral test as well as immuno-nephelometry with the Disc 
120 immuno-nephelometer (Hyland, Nivelles, Belgium). Data were collected in 10 general 
practices performing the Nijmegen Monitoring Project. At a regular check-up each type 2 
diabetic patient was asked to collect first morning urine samples on three consecutive days. 
Results The sensitivity of the Micral test was 67%, the specificity 93%. Between the practices 
the sensitivity ranged from 58% to 81%, the specificity from 87% to 95%. Microalbuminuria, 
defined as a mean unne albumin concentration -> 20 mg Γ1 by nephelometry on three 
consecutive days, was found in 66 patients (21%). The first Micral test correctly picked out 
these patients with microalbuminuria in 70% of the cases and in 90% those patients without 
microalbuminuria. The diagnostic performance of the Micral test was further proved by a 
Receiver Operating Characteristic (ROC) curve. The Area Under the Curve of the Micral test 
was 0.84 (95% CI 0.78 - 0.90). Micral-test result of 0 and 10 should be regarded as negative. 
Conclusion Our Micral test results suggested that the use of the Micral test in a general 
practice setting can be successful if strict standardised procedures are followed and repeated 
measurements are performed. 
Key words Microalbuminuria, type 2 diabetes. General Practice, Micral test 
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Introduction 
Microalbuminuria is defined as an albumin excretion rate (AER) of 20-200 μg min"1 in an 
overnight collection, or 30-300 mg 24h"1.1 It is thought to be related to a number of risk 
factors for cardiovascular disease2'5 and predicts the development of clinical proteinuria, 
early cardiovascular mortality,''""1 proliferative retinopathy," and nephropathy.0 Although 
only 3-8% of the type 2 patients with nephropathy develop end-stage renal disease,12 the 
prevalence of this type of diabetes turns renal failure into a quantitative relevant problem. 
Approximately 50% of all diabetes patients requiring dialysis or transplantation therapy are 
type 2 diabetes patients. It is obvious that renal replacement therapy negatively influences 
patients health, quality of life, and economic aspects. Antihypertensive treatment will at least 
slow down the progression from microalbuminuria to persistent proteinuria.15"17 The rate at 
which albumin excretion increases is related to long-term glycacmic control.18 However, it 
remains to be established whether antihypertensive treatment or strict blood glucose control 
will reduce the development of renal failure and cardiovascular morbidity and mortality. 
Moreover, the potential benefits of any screening and intervention have to be weighted 
against the costs of screening and treatment. 
Although early disease detection and treatment seems simple, in practice many prerequisites 
have to be fulfilled. ''' Gilbert recently reviewed the prognostic and therapeutic implications 
of microalbuminuria in diabetes mellitus." In agreement with former recommendations he 
concluded that screening for microalbuminuria seems justified.2122 Moreover, he addressed 
that screening helps to identify patients at high risk for retinopathy and cardiovascular 
diseases.20 Such patients in particular may benefit from more frequent and tight control.20 
As most type 2 diabetic patients are treated in general practice, an instrument to screen for 
microalbuminuria should be feasible in general practice. For this reason the collection of 
24-h or timed samples is inconvenient, especially when repeated measures are proposed. 
Moreover, an albumin concentration in a first morning urine sample of 20 mg Γ1 is a 
reasonable initial screening cut-off point for identifying patients with microalbuminuria.1'23"27 
Recently a cheap and simple to handle dipstick test for microalbuminuria (Micral-test) was 
evaluated in a clinical setting. In the hands of trained laboratory technicians the following 
were found: a sensitivity of 75-100%, a specificity of 80-97%) compared to 
radioimmunoassay,"1*" a predictive value of a positive test result of 55-72% and of a 
negative test result of 97%. The critical time of contact between stick and urine and 
reading may be a major source of error in the use of the strip under general practice 
conditions. 
The aim of this study was to assess the feasibility of screening a large diabetic population for 
microalbuminuria by means of the Micral test in a general practice setting. This study 
compares measuring albumin concentration in first morning urine on three consecutive days 
by means of the Micral test and by immuno-nephelometry. 
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Patients and methods 
Patients and study design 
First morning urine samples on three consecutive days of 401 type 2 diabetic patients were 
tested for microalbuminuria by means of the Micral test and by immuno-nephelometry. The 
immuno-nephelometric results served as reference values. 
Patients were selected from the Nijmegen Monitoring Project (NMP).1'' This is a longitudinal 
registration aimed at studying the course of type 2 diabetes mellitus and other chronic 
diseases in general practice. Since 1985 all type 2 diabetic patients in 10 general practices, 
including those who are under specialist medical care, have been included in this registration 
if the diagnostic evidence is in agreement with the WHO-cntena.'7 Patients who were treated 
with insulin within 1 year of diagnosis and who remained on it were regarded as Type 1 
diabetic patients. All other patients were regarded as type 2, irrespective of their current 
treatment. Monitoring consists of the follow-up of the level of metabolic control, diabetes-
related complications, cardiovascular morbidity, cardiovascular risk factors, and mortality. 
For this study all type 2 diabetic patients in the Nijmegen Monitoring Project under control 
of their general practitioner were invited to participate in the screening for microalbuminuria. 
The screening took place at their routine diabetes check-ups over a period of 1 year. All 
patients were asked to: 
1. collect first morning urine samples on three consecutive days; 
2. store these samples at 4 C (as this preserves the albumin concentration for up to 2 
weeks18); 
3. bring them to the practice on the morning of the third day 
All patients received instructions from the practice assistants and written explanation about 
the standardised procedures how to collect and store the urine samples On the third morning 
the patients brought their urine samples to the practice, these samples were first tested for 
nitrite and proteinuria by a dipstick test (N-combur test, Boehringer Mannheim, Germany). 
Samples with positive nitrite or albumin tests were excluded. All other samples were tested 
by the practice assistant by means of the Micral test. Aliquots of these samples were stored at 
4 C and analysed by immuno-nephelometry within 1 week of collection. 
Measurements of microalbuminuria 
The Micral test is an immunochemical strip lest specific for albumin. (Boehringer 
Mannheim, Germany) The reagent part of the test strip should be dipped into the urine for 5 
s, then laid down horizontally and read after 5 mm. The intensity of the colour produced is 
proportional to the albumin concentration in the urine. The colour formed is compared with 
the reference chart on the vial. There are five colour blocks, reflecting categories of albumin 
concentrations of 0, 10, 20, 50, 100 mg Γ1. Careful initial training was given to the general 
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practitioners (GPs) and practice assistants on the standardized procedures and performance of 
the Micral test. As reference values, albumin concentrations were also measured with the 
Disc 120 immuno-nephelometer (Hyland, Nivelles, Belgium) with an anti-serum raised in 
New Zealand white rabbits. Details of the immunisation procedure and the immunological 
nephelometric method were published earlier.1s The coefficient of variation between batches 
was 3% and 10% in high concentration (mean 70,1 SD 2.1) and low concentration (mean 5.3 
SD 0.6), respectively The coefficient of variation within batches was 1.8%. The detection 
limit was 1 mg I '. 
Analysis 
The day-to-day variation of the albumin concentrations of each patient was calculated by 
assessing the agreement between the albumin concentration on first, second, and third 
mornings measured by nephelometry (Bland-Altman plot)3 ' ' A cut-off point of 2=20 mg Γ1 
was used to differentiate subjects with microalbuminuria from subjects without 
microalbuminuria The sensitivity, specificity, predictive values, and likelihood ratios of the 
Micral test were based on the Micral test results of the first morning urine sample and the 
albumin concentrations measured in the same sample by immuno- nephelometry. The 
likelihood assesses the diagnostic power of a lest. It is the quotient of the chance to find a 
positive test result in a sick individual (nominator) and the chance of a positive test result in a 
healthy subject (denominator). For a test which does not discriminate between sick and 
healthy individuals the nominator and denominator are equal resulting in a likelihood ratio of 
1.0. The discrimination is better when the likelihood ratio for a positive test result is greater 
than 1.0 and for a negative test result when approximating zero. We calculated the reliability 
of the Mircal test to single out those patients without microalbuminuria, defined by the mean 
nephelometry result for the 3 days. 
A Receiver Operating Characteristic (ROC) curve was constructed by graphing the 
sensitivity on the y-axis against the false positive fraction (1-specificity) on the x-axis. The 
area under this curve gives a measure for the diagnostic power of a test. For a test which does 
not discriminate between sick and healthy people the resulting ROC curve coincides with the 
diagonal and will have an Area Under the Curve (AUC) of 0.5 A perfect test will have an 
Area Under the Curve of 1.0.A" 
Results 
A complete set of three consecutive first morning urine samples was collected from 401 type 
2 diabetic patients. Using the N-Combur-test, nitrite was found in one or more of the samples 
m 22 patients and albumin in 62 patients. Of the remaining 317 patients three urine samples 
were lesled by the Micral test and immuno-nephclometry. The day-to-day variation of 
albumin concentrations in the same patient was assessed by the mean difference between the 
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urine albumin concentration measured by nephelometry on first, second, and third morning 
and their mean (table 7-1). The day-to-day vanation seems to increase with the level of 
microalbuminuria. 
Table 7-1 The day-to-day variation of the urine albumin concentration as the mean 
differences from the mean on three consecutive days in the same patient. 
Level of albumin concentrationJ Sample 1 sample 2 sample 3 
0-9.9 (n=174) 
10-19.9 (n=77) 
20-49.9 (n=48) 
50-99 9 (n= 5) 
100-300 (n= 13) 
0.02 
2.1 
0.4 
-4.9 
23.5 
(13) 
(6 2) 
(9 6) 
(8 9) 
(71.2) 
0.00 
-1.5 
-0 6 
-9 5 
-15.2 
(1.2) 
(4.2) 
(102) 
(5 9) 
(62 8) 
-0.03 
-0.5 
0.3 
11 5 
-8 3 
(1.4) 
(5.1) 
(10.8) 
(8.3) 
(44.9) 
Results as mg Γ1 with standard deviation between parentheses 
" Mean urine albumin concentration on three consecutive da)s measuied b\ nephelometiy 
Sensitivity, specificity, predictive values, and likelihood ratios are based on the first Micral 
test (tables 7-2 and 7-3). It was reasonable to present only the result of the first morning 
sample of each patient as the other samples give the same information. A threshold of 20 mg 
Γ
1
 gives optimal balance between sensitivity and specificity. A threshold of 10 mg Γ1 gives a 
poor specificity (44%), a threshold of 50 mg I"1 a poor sensitivity (31%). If the categories 0 
and 10 were regarded as negative test results, the Micral test is a good instrument to identify 
subjects without microalbuminuria (specificity 93%). The test was less suitable to identify 
patients with an albumin excretion a 20 mg Γ1 (sensitivity 67%). 
We analysed the data under three conditions for microalbuminuria: 
1. Mean value of the three measurements for nephelometry > 20 mg 1"' (table 7-4). 
2. Median value of the three measurements for nephelometry > 20 mg Γ'. 
3. Two out of three nephelometry results > 20 mg Γ1. 
As results were virtually the same, we presented in this study the mean values. 
Microalbuminuria, defined as a mean albumin concentration > 20 mg Γ1 by nephelometry for 
three consecutive first moming urine samples, was present in 65 patients (21%). Of these 65 
patients, 12 had a Micral-test result > 20 mg Γ1 in none of the samples; 54 had one positive 
result, 47 had two and 39 three. The first Micral test correctly pick out these patients with 
microalbuminuria in 69% of the cases and in 92% those patients without microalbuminuria 
(table 7-4). 
The diagnostic performance of the Micral test was further proved by a ROC curve (figure 
7-1). The AUC of the Micral test was 0.84 (95% CI 0.78 - 0.90). 
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Table 7-2 Urine albumin concentrations as a result of first Micral test and 
immunonephelometry (Hyland-Disc 120). 
Micral Category 
0 
10 
20 
50 
100 
<20 
107 
116 
15 
2 
1 
Urine concentration by 
20.0^9.9 
5' 
16 
21 
12 
2 
nephelometry. 
50.0-99.9 
2-
1 
1 
2 
4 
mgl"1 
>100 
0 
1 
5 
2 
2 
Results as absolute numbers 
"All samples from one of the 10 participating practices 
Figure 7-1 Receiver Operating Characteristic curve of the Micral test in general practice 
(n= 317). The Area Under the Curve of the Micral test was 0.84 (95% CI 0.78 - 0.90). 
C/Î 40 -
20 40 60 80 
1 - Specificity (% false positives) 
100 
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Table 7-3 Evaluation of the Micral test compared to immuno-nephelometry (Hyland-Disc 
120) 
Screening cut-off point (mg Γ1) 
> 20 
Sensitivity Specificity PV +' PV-2 L R + 3 LR- 4 
67 93 74 90 9.6 0.35 
Results oj sensitivity, specificity und predictive values en peicenlages 
predictive value of a positive test result 
' predictive value oj a negative test result 
likelihood ratio of a positive lest result 
likelihood ratio of a negative test result 
Table 7-4 Reliability of the Micral test to identify patients with microalbuminuria defined as 
a mean urine albumin concentration ä 20 mg Γ in three consecutive first morning urine 
samples measured by nephelometry. 
Micral test * \ Microalbuminuria (mean > 20 mg Γ1) based on nephelometry b 
[ positive negative 
Positive0 ! 45 24 
Negative | 20 228 
" Mitral test result oj the first in ine sample 
' Mean based on three nephelometiy ι esults 
c
 Positive is defined as a result in the category 20, 50 οι 100 
Discussion 
We found that in a general practice setting the Micral test has good specificity and moderate 
sensitivity at the cut-off point of an urine albumin concentration of 20 mg Γ1. The frequency 
of false positive results (1-specificity) was 7%, occurring in 8% of the study population. 
Since the Micral test is a screening test and not a diagnostic test, this number of false positive 
results is acceptable. The sensitivity of the Micral test was lower in our study than in the 
clinical setting.29'32 The frequency of false negative results (1-sensitivity) was 33%, occurring 
in 6% of the study population. This means that Micral test has limited value for identifying 
patients with microalbuminuria. In screening, a fairly high false negative rate is only 
acceptable if at the next screening the missed cases are detected still at a pre-climcal stage. 
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Cooper found that the mean duration of the microalbuminuric phase was 3 to 4 years, with 
considerable individual variation.41 So the use of the Micral test can be supported if repeated 
measurements are performed. These repeated measurements probably identify patients with 
progression of proteinuria. According to our results 75% of the patients with 
microalbuminuria were classified correctly by two out of three Micral tests (false negative 
25%). The AUC of the ROC curve (0.84) of the Micral test indicates good discrimination 
between patients with and without microalbuminuria using a cut-off point of 2. 20 mg Γ1. 
There were some differences between the 10 general practices. In one practice (n=66) the 
sensitivity of the Micral test was 58% and the specificity 87%. In another practice (n=59) a 
sensitivity of 81% and a specificity of 95% was found. The range in sensitivity emphasizes 
how difficult it is to perform correctly a Micral test in a general practice setting. Poulsen 
evaluated the Micral test in three settings: 
1. trained nurses; 
2. laboratory technicians; 
3. general practice. 
The specificity of the Micral test was high (85-97%) in all settings. However he found a 
decrease in sensitivity from almost 90% in laboratory technicians to 66% in the general 
practice setting. Jury showed that the depth of dipping the strip into the unne sample and 
the time of reading the colour were critical.11 Marshall studied the time dependency of the 
test by comparing the results obtained for strips that were in contact with urine for 2 and 5 s 
and by reading at 4, 5, and 6 min. Contact with urine for 2 s rather than the recommended 5 s 
resulted in an underestimation of the unne albumin concentration, as did taking readings 
earlier than the recommended 5 min. ^ This time dependency is a serious problem in general 
practice as the practice assistant has to perform diagnostic tests during other activities, such 
as telephone calls and patient contacts. Tiu demonstrated a considerable inter-observer 
variation in the matching of colours for the Micral test.28 
These, as well as our results, clearly demonstrate the necessity of careful initial training, 
follow-up training, and a quality-control system to ensure continuing satisfactory 
performance of the Micral test. A limitation of the Micral test, as of all methods that measure 
urine albumin concentration, is the influence of diuresis. The wide day-to-day variations of 
diuresis and urine albumin excretion make it necessary to confirm an abnormal albumin 
concentration in first morning urine with a second test. In order to confirm diagnosis repeated 
abnormal results require ideally a timed unne collection. However, the correct collection of 
timed samples, even if the patient knows that he or she is at risk for nephropathy, may be 
very difficult. The measurement of albumin/creatinine ratios may be more reliable. 
Based on the screening strategy proposed by the Si. Vincent declaration' and our findings, 
for general practice we suggest the screening strategy outlined in figure 7-2. Patients with a 
Micral test result of 0 are highly unlikely to have a urinary albumin concentration 220 mg Γ , 
so these patients only need to be re-screened after 1 year. Approximately 40% of the type 2 
diabetic patients in our study had a Micral test result of 10 mg Γ1 Nearly 20% of them had an 
albumin concentration > 20 mg Γ1. It seems sensible to perform another Micral test in those 
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patients within 4 weeks. If the second Micral test result falls into the category > 20 mg Γ 
further diagnosis is required. In all other cases re-screening after 1 year seems justified. 
Figure 7-2 Screening strategy Micral test in general practice. Patients with a Micral test 
result of 0 are highly unlikely to have a urinary albumin concentration > 20 mg I , so these 
patients only need to be re-screened after one year. 
In patients with a Micral test result of 10 it is sensible to perform another Micral test within 
4 weeks. If the second Micral test result falls into the category > 20 a timed quantitative 
measurement is recommended. In all other cases re-screening after one year seems justified. 
In patients with Micral test results of 20, 50 or 100 we propose a second Micral test within 4 
weeks. If the second Micral test result falls again into the category > 20 a timed quantitative 
measurement is recommended. In all other cases re-screening after one year seems justified. 
First morning urine sample 
Albumin concentration 
- Micral 0 me 1 ' 
Timed urine samples 
within 6 - 12 weeks 
Micral test results of 20, 50 or 100 mg Γ1 are clearly found almost exclusively in those 
patients with an albumin concentration > 20 mg Γ1. In those cases we propose a second 
Micral test within 4 weeks. If the second Micral test result falls into the category > 20 mg Γ1 
further diagnosis is required. In all other cases re-screening after 1 year seems justified. 
We compared two strategies in terms of cost effectiveness. Both are based on albumin 
concentrations in first morning unne samples and using an albumin concentration threshold 
of 20 mg Γ1: Strategy 1: screening using nephelometry and strategy 2: screening using Micral 
test. The cost of the nephelometry assay was £ 10.40 and that of the dipstick £ 1.28, based on 
the Dutch real costs (assay-dipstick cost ratio 8.1). The cost effectiveness of this screening 
strategy was calculated in a fictitious cohort of 100 diabetic patients. 
STRATEGY 1: all patients are screened with nephelometry. The costs include a first test for all 
patients and a second test for patients with results on first screening > 20 mg I ' (about 20%). 
(100 + 20) χ 10.40 = £ 1248 (exclusive of costs due to the storage and the transport at 4 C of 
the unne samples from the practice to the laboratory). 
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STR4TE(IY 2 all patients screened with Micral test The costs include a first dipstick for all 
patients and a second dipstick for patients with results on first screening > 0 (about 65%): 
(100 +65) χ 1 28 = £211 20 
Floch studied the cost-effectiveness of screening for microalbuminuria using the Micral test 
or laboratory assay in an fictitious cohort of 10 000 diabetic patients (Type 1 and 2 ) 3 3 He 
staled that the cost-effectiveness of the Micral test was strongly related to the frequency of 
false negative results In that study the frequency of false negative results was 9 2% (the 
Micral test was performed in a clinical setting), if increased to 15-20% the effectiveness 
decreased dramatically The frequency of false negative results in our study was even higher 
Although the practice assistants GPs received initial training, follow-up training and quality-
control might have contributed to a higher sensitivity 
Apart from the cost reduction in strategy 2 of almost 85%, the Micral test has the practical 
advantage that the result is immediately available during the patient's visit Moreover, the 
urine samples do not have to be stored at 4 C and send to a laboratory 
In conclusion, screening for microalbuminuria in type 2 diabetic patients is still a 
controversial topic because il has to be proven whether interventions can delay the 
development of renal failure, cardiovascular morbidity, and mortality However, there is 
growing evidence in favour of screening for microalbuminuria As most type 2 diabetic 
patients are treated in general practice such a screening should be easily applicable in that 
setting Our results suggest that the use of the Micral test can only be supported if strict 
standardized procedures are followed and repeated measurements are performed 
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Summary 
Aims To assess the course of microalbuminuria m type 2 diabetic patients in general 
practice and the predictive value of urinary albumin concentration on all cause mortality, 
cardiovascular mortality and cardiovascular morbidity. 
Methods Cohort study in type 2 diabetic patients tested for microalbuminuria in 1992, and 
retested in 1998. During follow-up all cardiovascular morbidity and mortality were recorded. 
Results Of the original sample of 317 patients, 163 patients were retested. The mean change 
in urinary albumin concentration was +16.2 mg Γ1 (range: -122.0 to +602 mg Γ1). 75% of the 
patients without microalbuminuria in 1992 still had no micro-albuminuna in 1998 and 40% 
of those with microalbuminuria in 1992 reverted to normoalbuminuna in 1998. 
Cox survival analysis, stratified for age, showed that microalbuminuria at baseline resulted in 
a risk ratio of all-cause mortality of 1 4 (95% CI 0.8 - 2.7), of cardiovascular mortality of 1.2 
(95% CI 0.5-2 8) and of new cardiovascular events (including cardiovascular mortality) of 
1.4 (95% CI 0.8-2 3). 
Conclusions In the majority of patients the change of urinary albumin excretion was small, 
but the range was wide. A weak non-significant relationship between microalbuminuria and 
all cause mortality and cardiovascular morbidity was observed. 
Keywords cardiovascular morbidity, general practice, microalbuminuria, mortality, type 2 
diabetes mellitus 
List of abbreviations 
normoalb = normoalbuminuna; 
microalb = microalbuminuria; 
macroalb = macroalbuminuria; 
GP = General Practitioner. 
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Introduction 
Microalbuminuria, an albumin excretion rate of 20-200 μg/mln', predicts early 
cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus.2,3''1 This 
appears to be related to disturbances in coagulation, endothelial dysfunction and lipoprotein 
levels ^ ' However, it is not proven that treatment of microalbuminuria reduces 
cardiovascular morbidity or mortality. 
Microalbuminuria is also related to the development of proteinuria.2 The precise relation 
between the occurrence of microalbuminuria and the glomerular filtration rate in patients 
with type 2 diabetes is still uncertain. Tight blood pressure control in normotensive type 2 
diabetic patients with mircroalbuminuna can stabilize the urinary albumin excretion and 
plasma creatinine levels,7'8 although there is some dispute as to the effects on plasma 
creatinine concentration. l ,'") 
A fundamental problem with respect to the development of nephropathy and end-stage renal 
disease in type 2 diabetic patients concerns incomplete knowledge about the course of 
microalbuminuria. ' * 
The aims of this study were to describe the course of microalbuminuria in type 2 diabetic 
patients in general practice over a 6-year period, and to assess the predictive value of baseline 
urinary albumin concentration on cardiovascular morbidity and mortality. 
Patients and methods 
Patients and study design 
A cohort study was performed in patients with type 2 diabetes from 10 general practices of 
the Nijmegen Monitoring Project (NMP).1 '1 4 All type 2 diabetic patients previously tested 
for microalbuminuria in 1992, were invited for a second lest in 1998 using to the same strict 
protocol, first morning urine samples on 3 consecutive days, stored at 40C and analysed with 
Behring Nephelometer analyzer II (Marburg, Germany).1 '1 ' s No specific intervention was 
undertaken based on the results in 1992. During follow-up, all patients were strictly 
monitored and treated according to the Guidelines of The Dutch College of General 
Practice' '' and all cardiovascular morbidity and causes of death were recorded by GP 
according to the International Classification of Health Problems in Primary Care 
(ICHPPC).'7 
Statistical analyses 
To assess the relation between the baseline value and the change of urinary albumin 
concentration between 1992 and 1998, Spearman rank correlation coefficients and chi-square 
tests were performed To describe changes in the presence of microalbuminuria, this 
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condition was defined as two out of three results of 20-200 mg.!"1. Macroalbuminuria was 
defined as two out of three results of >200 mg. Γ1. 
Survival data were analysed using statistical methods for censored failure times. Baseline 
variables examined, by means of univariate Cox proportional hazards regression stratified by 
age, as possible confounders of any relationship between urinary albumin concentration and 
death analysis were: sex, duration of diabetes (continuous), body mass index (continuous), 
therapy for diabetes mellitus (diet only / one oral hypoglycaemic agent / combination of 
hypoglycaemic agents / insulin), cardiovascular morbidity (absent/present), hypertension 
(antihypertensive treatment after blood pressure that averages over 160/95 mmHg at three or 
more encounters, absent/present), systolic and diastolic blood pressure at baseline 
(continuous), HbAlc during follow-up (continuous), hypercholesterolaemia (cholesterol £ 
6.5 mmol, absent/present). Initial urinary albumin concentration was classified into two 
categories: normoalbuminuria (two out of three nephelometry results < 20 mg.!"') and 
microalbuminuria (two out of three nephelometry results 20-200 mg.!"') according to 
international guidelines. ' Subsequently, a multivariate analysis was performed using the Cox 
proportional hazards regression procedure. 
Results 
Of the original sample of 317 patients in 1992'4, 13 were reclassified as type 1 diabetes 
mellitus and 42 dropped out, 38 because their GP had resigned from this study and four 
records were lost. The remaining 262 patients were included in the survival analysis. Of these 
patients, 57 died and 27 had moved or went to an nursing home. One hunderd and seventy-
eight patients were therefore approached for remeasurement of microalbuminuria. The 
clinical baseline characteristics of both study groups are presented in table 8-1. 
Course of microalbuminuria 
Microalbuminuria was successfuly remeasured in 163 patients (response 92%). Ten patients 
with a urinary tract infection (nitrite test positive, using N-Combur-test) were excluded from 
further analyses. During follow-up mean HbAlc was 7.4% (SD 1.3), mean blood pressure 
150/82 mmHg (SD 19/9), mean cholesterol 5.7 mmol/1 (SD 1.1) and mean HDL cholesterol 
1.2 mmol/1 (SD 0.4). The Spearman correlation coefficient between the mean urinary 
albumin excretion in 1992 and 1998 was 0.54 (p=0.0001). As the mean baseline value and 
the change in urinary albumin excretion were not statistical significantly related (correlation -
0.11, p= 0.14), it was more appropriate to express the change of microalbuminuria in terms 
of absolute change rather than as a percentage of the baseline level of microalbuminuria. 
Mean change in unnary albumin concentration was +16.2 mg.Γ , ranging from -122.0 to 
+602 mg.!"1. Excluding those patients who developed macroalbuminuria (n=5), the mean 
change in urinary albumin concentration was +3.5 mg.!"' An urinary albumin excretion 
decrease of more than 10 mg.!"' was present in 16 patients (10%), while 30 patients (20%) 
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showed an increase of more than 10 mg.!"'. The highest quartile of the change in urinary 
albumin excretion was related to duration of diabetes (p=0.03). No other baseline variables 
(see table 8-1), nor mean HbAlc or mean blood pressure during follow-up, were statistically 
different between highest and lower quartile groups. 
Table 8-1 Baseline characteristics (1992) of the study population. 
Survival analysis Remeasurement 
microalbuminuria 
Total Normoalb Microalb Approached Succeeded 
(n=262) (n=212) (n=50) (n=178) (n=163) 
Ì 
Age (years) ! 
Male sex (%) 
Years diabetes 
Body Mass Index (kg/height2) 
Cardiovascular morbidity (%) " 
Hypertension (%) 
Mean systolic BP mmHg 
Mean diastolic BP mmHg 
Hypercholesterolaemia (%)r 
'p < 0 05 
" Al U'ti.st one of the following diagnoiei defined according to the International Classification of Health 
Problems in Pnmaiy Care (ICHPPC) myocardial infarction, angina pecions. heart jailure. cerebrovascular 
accident, trans ischemic a/lack, peripheral vascular disease 
Hypertension defined as antihypertensive treatment after blood pressure that averages over 160/95 mmHg at 
three or more encounters 
Mean cholesterol of two measurements 2 6 5 mmol/l 
Changes in the presence of microalbuminuria, between 1992 and 1998 are shown in table 
8-2: 75% of the patients without microalbuminuria in 1992, still had no micro-albuminuria in 
1998 and 40% of those with microalbuminuria in 1992 reverted to normoalbuminuria in 
1998. 
66(11) 
39 
5.0(3.4) 
28.9 (0.3) 
28 
38 
155(21) 
82(10) 
22 
66(11) 
36 
4.8(3.1) 
28.8(5.1) 
27 
38 
150(21) 
82(10) 
23 
65(12) 
52' 
5.6 (4.2) 
29.4(6.2) 
32 
38 
152(21) 
84(10) 
18 
63(11) 
35 
4.6 (2.9) 
29.6 (5.7) 
23 
39 
148(21) 
84(10) 
25 
64(10) 
34 
4.7 (2.9) 
29.4(5.8) 
24 
40 
150(21) 
82(11) 
26 
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Survival analysis 
At baseline 50 of the 262 patients had a micro-albuminuria (prevalence 19%). During follow-
up 57 patients died: 13 patients of 50 with initial microalbuminuria (26%) and 44 of 202 
without initial normoalbuminuria (22%). There were no statistically significant differences 
between causes of death in patients with and without microalbuminuria. Cardiovascular 
disease was the most prominent cause of death (n=36, seven in patients with and 29 in 
patients without microalbuminuria). None of the patients died as a result of renal failure. 
Cox survival analysis, stratified for age, showed that microalbuminuria at baseline resulted in 
a risk ratio of all-cause mortality of 1.4 (95% CI 0.8 - 2.7), of cardiovascular mortality of 1.2 
(95% CI 0.5-2.8) and of new cardiovascular events (including cardiovascular mortality) of 
1.4 (95% CI 0.8-2.3). All cause mortality, stratified for age, was statistical significantly 
different for male gender (p=0.02) and duration of the diabetes (p=0.02). After adjusting for 
these confounding variables microalbuminuria at baseline resulted in a risk ratio of all-cause 
mortality of 1.2 (95% CI 0.6 - 2.2). 
Table 8-2 Changes in presence of microalbuminuria in type 2 diabetic patients in general 
practice over a six year period. 
1992 1998 
Category η meand Category % η meand 
75 103 6.7(5.5) 
17 23 58.9(45 6) 
1 2 543(107) 
7 10 
40 10 8.9(4.6) 
48 12 57.3(49.1) 
12 3 387(182) 
" normoalbuminuria (normoalb) defined ai two oui of three nephelomeliy reudh < 20 mg Γ 
microalbuminuria (microaib) defined ai two out of three nephelomeliy resulti 20 - 200 mg Γ' 
r
 macToalbummuna (macroalb) defined as two out ofthiee nephelomeliy results > 200 mg t 
mean urinary albumin concentration by nephelomeliy standard deviation between puientheses 
Discussion 
Normoalb ' 
Microalb 
138 9.6 (4.7) 
25 55.5(51.1) 
^ 
^ 
Normoalb 
Microalb 
Macroalb 0 
nitrite pos 
Normoalb 
Microalb 
Macroalb 
This study showed that the mean change of urinary albumin excretion in type 2 diabetic 
patients in general practice over a six year period was small. However, the range of change 
was wide. 
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A longitudinal inconsistency in the course of microalbuminuria in type 2 diabetic patients has 
been described in clinic based studies , · l 8 ' l ' , and in newly diagnosed type 2 diabetic 
patients ''2" The percentages of patients in our study with initial normoalbuminuria that 
developed microalbuminuria (17%) and with initial microalbuminuria that reverted to 
normoalbuminuria (40%) were comparable with earlier studies.'1'21'22 Five patients in our 
study developed macroalbuminuria, a low figure as prevalence rates for proteinuria have 
been reported up to 15-40% in type 2 diabetes after at least 10 years duration.23'24 However, 
Gall el al. have reported similar results.21 
Although the data suggest a relation between the presence of microalbuminuria and all cause 
mortality and the occurrence of cardiovascular events, the results were not statistically 
significant. Earlier general practice or community-based studies found higher, but also not 
statistically significant, risks of cardiovascular morbidity and cardiovascular mortality ' ' , 
with one study reporting significantly increased all cause mortality. '' Pooled results of 
community and secondary care-based studies showed considerable higher, statistically 
significant. Odds ratio's for all cause and cardiovascular mortality 
The present study has limitations. First, microalbuminuria was measured cross-sectionally 
and patients differ in duration and stage of the disease. Moreover, survival of the fittest 
patients may have biased the cohort. Second, the course of microalbuminuria was influenced 
by the GP's treatment during follow up. Third, the number of patients were small. 
Nevertheless, our study adds general practice based evidence of the course and predictive 
value of microalbuminuria. The small change in urinary albumin excretion in the majority of 
our patients during 6 years' follow-up and at the same time the broad range of this change 
found, underlines the problem in establishing the role of microalbuminuria in the treatment of 
type 2 diabetes." 
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Summary and discussion 
Main results 
This study addressed the long-term impact of type 2 diabetes mellitus on patients treated in a 
general practice setting. The life expectancy of type 2 diabetes patients newly diagnosed 
between 1967 and 1989 in four Dutch general practices was diminished. Compared to non-
diabetic controls type 2 diabetic patients had higher cardiovascular morbidity (risk ratio 1.76, 
95% CI 1.34 - 2.30) and higher total mortality (risk ratio 1.54, 95% CI 1.07 - 2.23). Higher 
mortality was due to cardiovascular deaths (risk ratio 2.05, 95% CI 1.24-3 37). In addition, 
patients with type 2 diabetes mellitus were 2.5 (95% CI 1.5 - 4 1) times more likely to be 
suffering from functional impairment than controls. This was related to cardiovascular 
morbidity, locomotory morbidity and the diabetes itself (odds ratio 1 4, 95% CI 1.1 -1.9). 
Thus type 2 diabetes in a general practice setting was found to be associated with higher 
cardiovascular morbidity, decreased functional health status and diminished life expectancy. 
These findings underline the importance of preventing or postponing cardiovascular 
morbidity in type 2 diabetes mellitus in a general practice setting. Tight metabolic control in 
combination with state-of-the-art management of cardiovascular risk factors has been 
recommended. 
We introduced an audit enhanced monitoring system into a general practice research setting 
and subsequently achieved outcomes of diabetes care that were comparable with those 
reported in RCTs. Seven years after the introduction of the audit enhanced monitoring system 
the average HbAlc level had dropped substantially. Only a small group (13% compared to an 
initial 41%) had persistently elevated levels (HbAlc > 8 5%)) Total cholesterol had also 
improved from 6.2 mmol/1 to 5.4 mmol/1 (p=0.001). In 1993, 48% of the patients exceeded 
the targets for lipids compared to 28% in 1999 (p=0 001). Mean blood pressure (150/82 
mmHg) and the percentage of patients above the target blood pressure (systolic 46%, 
diastolic 34%) did not change. 
These long-term outcomes were accompanied by an increase in the percentage of patients 
who attended an annual check-up (73%) vs 84%)). Thus, the outcome in 1999 was based on a 
larger percentage of patients. As no patient-related factors were associated with attending the 
annual check-up, we are confident that the findings reflect improved overall diabetes care. 
The new monitoring system offered the opportunity to select patients that needed special 
attention: patients with poor glycaemic control despite maximum oral medication. Starting 
insulin therapy in these patients resulted in clinically significant improvement in glycaemic 
control (HbAlc decreased from 9.5% to 7.6%, ρ < 0.001). This was accompanied by a reduction 
of hyperglycaemic complaints (p=0.01), no increase in hypoglycaemic complaints and no 
adverse influence on functional health status. In this way tight metabolic control could be 
achieved in general practice. 
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Methodological issues 
Employing different groups of control subjects influenced the statistical findings with respect 
to mortality risk in type 2 diabetes patients. Choosing controls without any cardiovascular 
risk factors, cardiovascular morbidity or other serious diseases increased the relative mor-
tality risk in type 2 diabetic patients from 1.67 (95% CI 1.16 - 2.40) to 2.16 (95% CI 1.46 -
3.20). Excluding controls with chronic psychosocial problems decreased the relative 
mortality risk in type 2 diabetic patients (1.33 95% CI 0.97 - 1 81). Thus comorbidity and 
chronic psychosocial problems in control subjects are likely to play a role in the outcome of 
clinical research. These aspects can be qualified and quantified in general practice research 
networks. 
Our Micral test results (a semiquantitative dipstick test to assess microalbuminuria) 
suggested that the use of the Micral test in a general practice setting will only be successful if 
strict standardised procedures are followed and repeated measurements are performed. 
Sensitivity (58% to 81%) and specificity (87% to 95%) varied widely between practices. 
In 1992, microalbuminuria, defined as a mean urine albumin concentration of ä 20 mg Γ1 
determined with nephelometry on three consecutive days, was present in 21 % of the patients 
(n=66). In 1998, the change in unnary albumin excretion was small in the majority of 
patients, but the range was wide; 75% of the patients without microalbuminuria in 1992 did 
not have microalbuminuria in 1998; 40% of those with microalbuminuria in 1992 had 
reverted to normoalbuminuna in 1998. A weak non-significant relationship was observed 
between microalbuminuria and all-cause mortality and cardiovascular morbidity. Cox 
survival analysis, stratified for age, showed that microalbuminuria at baseline resulted in a 
risk ratio of 1.4 (95% CI 0.8 - 2.7) for all-cause mortality, 1 2 (95% CI 0.5-2.8) for 
cardiovascular mortality and 1.4 (95%CI 0.8-2.3) for new cardiovascular events (including 
cardiovascular mortality). 
Our study provided general-practice-based evidence of the course and predictive value of 
microalbuminuria. The problem of establishing whether microalbuminuria plays a role in the 
treatment of type 2 diabetes was underlined by the small change in urinary albumin excretion 
in the majority of our patients during 6 years of follow-up, the wide range of this change and 
the weak non-significant relationship between microalbuminuria and all-cause mortality and 
cardiovascular morbidity. 
Strengths and limitations 
The study provided general-practice-based data on the long-term impact of type 2 diabetes 
mellitus on the clinical end-points mortality and cardiovascular morbidity. As most patients 
with type 2 diabetes mellitus are treated by their general practitioner, these results are 
particularly relevant for routine daily practice. The 1985 WHO diagnostic criteria for 
diabetes mellitus and definition of type 2 diabetes mellitus were strictly applied. All type 2 
diabetic patients were included without exception in contrast with RCTs, in which patients 
with (severe) co-morbidity and older patients are usually excluded. We were therefor able to 
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compare the effectiveness of normal daily GP care to outcomes under trial conditions 
(efficacy). ' 
The improvements in the quality of care at the participating practices were achieved by 
introducing the process of quality assessment in a stepwise manner over several years. In our 
opinion, the most important steps were the introduction of well-defined criteria for data 
gathering; well-structured registration; systematic feedback; selection of new items for 
feedback in consultation with the participating GPs; audit sessions in which feedback was 
given. 
Our study design enabled us to follow an unselected well-defined primary care population of 
type 2 diabetic patients over many years at well-organised practices with co-operative 
physicians who attended audit sessions and were closely involved in the process of 
improving the quality of care. 
Some limitations should also be mentioned. 
Firstly, the ten practices of the academic research network had a limited number of type 2 
diabetic patients, which have restricted the power of the study with respect to relatively rare 
clinical end-points. Secondly, data gathering took place during normal daily GP care. The 
participating GPs provided individualised care to patients which caused potential problems 
with the completeness and standardisation of data gathering To ensure that data were 
collected according to our protocol, these concern received close attention during the 
monthly meetings of the participating GPs. Moreover, to facilitate and standardise data 
collection, a computerised Research Registration System (RRS) was developed and integrated 
into a standard Dutch electronic record system for general practice (Promedico, Euroned). It 
was also important that the group of participating GPs did not change significantly in the 
period 1988 to 2000. Consistent supervision of patients supported complete and standardised 
data collection in this study. Thus, it has to be emphasized that the outcomes of this study 
cannot - and should not - be generalised to 'routine' general practice. They indicate the 
investment required to achieve such outcomes in general practice and what is possible in 
general practice under favourable conditions. 
Another point of discussion is the level of analysis. We analysed the results on a patient 
level, which revealed practice variation in the long-term outcome of diabetes care. This 
suggests that outcome in different patients from the same practice may not be independent, 
with 'good practices' obtaining 'belter outcomes' 
Remarks and recommendations 
Benchmarking and transparency of care 
The St Vincent declaration" reaffirms the importance of monitoring and evaluating care. The 
drive behind this declaration was the realization that in many health care systems, doctors are 
unaware of the impact of diabetes. A major consequence of this lack of awareness is that the 
quality of diabetes care has remained below a desirable level, while the standard of care 
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actually achieved has rarely been measured.2'3 Nowadays we have recognised the importance 
of regularly reviewing each patient's status, with systematic searching for risk factors and 
early manifestations of complications linked to a programme of corrective action and follow-
up visits to monitor a patient's response to treatment. This almost invariably requires the 
development of comprehensive patient registers and computerised information systems.4'5'6'7 
Comprehensive registers can serve as the basis for collecting data to make the work of the 
GP transparent and enhance structural measures to support primary care.8 However, little is 
known about the cost-effectiveness of such registration systems. 
Results obtained with comprehensive registers must be reviewed with caution, because the 
denominator is an important issue. Firstly, the population from which the type 2 diabetic 
patients are derived (the population at risk) must be clear and well-defined. Secondly, the 
inclusion or exclusion of subgroups of patients can substantially influence the results and 
hence the 'measured' quality of care. Patients refusing to take part or droping-out may cause 
bias. It is likely that the patients who refuse regular care will benefit the most from 
monitoring. Our study indicated that most patients became compliant to structured care after 
receiving the necessary education and they agreed with the treatment goals and objectives. 
However, a small proportion of the patients did not agree or were unable to take part; this 
may be a special group with more complex comorbidity and impaired functional health. 
Thirdly, care auditing generally focuses on the process of care, but it is the outcome that 
counts. Patient satisfaction and quality of life cannot usually be measured using standard 
biochemical and pathophysiological markers employed in routine care. 
Fourthly, as large numbers of patients with type 2 diabetes are treated in general practice, 
monitoring should fit into the overall primary care function of general practice. Structured 
records are particularly important to support data entry at the time of clinical contact. The 
standard Dutch electronic record systems currently available for general practice do not offer 
such facilities. 
Last, it has to be emphasized that benchmarking alone is not enough to improve the quality 
of care.' Care assessment should preferably take a more comprehensive approach, in which 
evidence-based goals for care are formulated, care is improved to reach these goals and care 
is measured to see whether these goals are achieved. 
Quality of Life 
Efforts to achieve an optimal disease-specific outcome may damage quality of life, 
particularly in the case of chronic diseases. Assessing the impact of treatment on quality of 
life is important for many reasons, not least because an adverse impact could reduce 
treatment compliance. However, measuring quality of life is difficult and results can be 
misleading.'I''2 Great precision is needed in the use of the term 'quality of life'. All quality of 
life (QoL) questionnaires, disease-specific and generic, measure particular aspects of quality 
of life. The term quality of life misleadingly suggests an abstract and philosophical approach, 
but most QoL questionnaires do not attempt to include more general notions such as life 
satisfaction, but rather concentrate on aspects related to health.13 Nevertheless, if the aspects 
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being measured are clearly described and defined, then such measures can provide insight 
into consequences of disease or treatment that cannot be measured by usual clinical 
parameters. 
Most instruments to measure 'quality of life' are lime-consuming and cannot be used in daily 
practice. Generally, more attention has been paid to the use of QoL instruments in clinical 
trials than to examine their value in routine clinical care. Short-form generic instruments 
suitable for clinical practice settings are a welcome development. These instruments have to 
be tested against more comprehensive and detailed ones to identify information that may be 
lost using brief assessments.14 In this respect our findings with the COOP/WONCA charts 
were interesting. 
The role of guidelines 
Our study demonstrated the impact of cardiovascular morbidity in type 2 diabetic patients on 
life expectancy and quality of life. These findings underline the importance of systematic 
follow-up for cardiovascular risk factors and cardiovascular morbidity in the treatment of 
type 2 diabetic patients as is recommended in several guidelines.1'''"'''7 However, 
implementing new routines with a view to improving patient care is difficult9'8 and the 
formulation of clinical guidelines alone is insufficient to improve actual care.19 We found 
that monitoring the clinical condition of the patient over several years, introducing evidence-
based guidelines, giving feedback to the clinician about the outcome, auditing clinical 
performance and academic detailing, improved the outcome of care. Moreover, monitoring and 
feedback with systematic follow-up of relevant treatment targets enhanced a pro-active 
approach of patients, which is a key factor for successful diabetes care "" 
Micro-albuminuria 
End-stage renal failure in type 2 diabetic patients is a rare phenomenon in general practice, 
probably due to premature cardiovascular mortality in these patients.*1 However, the prevalence 
of type 2 diabetes mellitus means that renal failure is a quantitatively relevant problem. 
Approximately 50% of all diabetic patients who require renal dialysis or transplantation have 
type 2 diabetes. It is obvious that renal dialysis or transplantation have a strongly negative 
influence on patient health, quality of life and economic aspects. Therefore the prevention of 
progression to renal failure and the prevention of cardiovascular morbidity and mortality are 
important targets in the treatment of type 2 diabetic patients. However, the role of screening for 
microalbuminuria in type 2 diabetes in general practice is still controversial." Although it may 
be acceptable to consider micro-albuminuria as a marker of proteinuria in type 2 diabetes 
mellitus, the role of microalbuminuria in the relation to eventual decline in renal function is 
unclear. There is insufficient evidence that screening and treatment for microalbuminuria in type 
2 diabetes patients affects clinical outcome or improves quality of life. It is unclear whether 
microalbuminuria found cross-sectionally predicts persistent albumin loss 2 1 · 2 ' ' 2 ( ' Moreover, the 
definition of microalbuminuria is based on the fact that an albumin excretion of 20-200 μg/min 
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predicts progression to diabetic nephropathy in type 1 diabetic patients. There is scarce 
evidence to justify the use of this definition in type 2 diabetes mellitus. Should we use another 
definition in type 2 diabetes: patients with a higher albumin excretion rate or patients with a 
progressive albumin excretion rate? On the other hand, even minor elevations in albumin 
excretion are associated with excess mortality in patients with type 2 diabetes mellitus.28 Can 
tight control of creatinine clearance in each patient better identify individuals that probably need 
special attention in the form of light blood pressure control and adjustment of the dosage of 
medication to renal function? 
These shortcomings in our clinical understanding of the role and course of microalbuminuria in 
type 2 diabetic patients justify further research in general practice, not least because of the 
tremendous consequences of renal replacement therapy. 
Final conclusions 
For many years, general practitioners and patients have not been convinced about the impact 
of type 2 diabetes mellitus and the need to improve care. General practitioners claimed that 
most studies on patients with type 2 diabetes mellitus were performed in clinical settings and 
the results were biased by referral, while the majority of type 2 diabetic patients did not have 
any symptoms and denied the severity of the disease Our studies demonstrated that type 2 
diabetes had considerable impact on life expectancy and functional health status in an 
unselecled population of type 2 diabetic patients from general practice. The long-term results 
of our audit enhanced monitoring system showed the potential for improving the outcome of 
diabetes care in a general practice setting. Starting insulin therapy in patients with poor 
glycaemic control resulted in clinically significant improvement in glycaemic levels without 
any adverse influence on functional health. Desired effects of treatment, i.e. to prevent or 
postpone cardiovascular disease - tightening metabolic control could be achieved in general 
practice 
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Samenvatting en discussie 
Belangrijkste bevindingen 
Deze studie richtte zich op de lange termijneffecten van diabetes melhtus type 2 bij mensen 
die hiervoor onder behandeling zijn bij de huisarts. Van mensen, bij wie in de periode tussen 
1967 en 1989 in vier Nederlandse huisartspraktijken diabetes melhtus type 2 was vastgesteld, 
bleek de levensverwachting verminderd. Vergeleken met personen zonder diabetes mellitus 
was het relatieve risico op het optreden van hart- en vaatziekten 1.76 (95% Cl 1.34 - 2.30) en 
het relatieve risico op overlijden 1.54 (95% Cl 1 07-2 23). Dit toegenomen sterfterisico werd 
veroorzaakt door een toegenomen sterfte aan hart- en vaatziekten (RR 2.05, 95% CI 1.24-
3.37). Bovendien bleken mensen met diabetes melhtus type 2 een 2.5 (95% Cl 1 .5-4 .1) 
maal hogere kans te hebben op (het ervaren van) functionele beperkingen dan mensen zonder 
diabetes melhtus. Dit hing samen met hart- en vaatziekte, ziekten van het bewegingsapparaat 
en diabetes melhtus zelf (odds ratio 1,4 95% Cl 1.1 - 1.9). Het optreden van hart- en 
vaatziekten bij mensen met diabetes melhtus type 2 in de huisartspraktijk ging dus niet alleen 
gepaard met een afgenomen levensverwachting maar in de voorafgaande jaren bovendien 
met een toename in functionele beperkingen. 
De bevindingen onderstrepen hoe belangrijk hel is om in de luusartspraktijk hart- en 
vaatziekten te voorkomen dan wel uit te stellen bij mensen met diabetes melhtus type 2. 
Hiertoe wordt een strikte metabole controle aanbevolen, in combinatie met een systematische 
aanpak van cardiovasculaire risicofactoren. Het onderzoek heeft aangetoond dat door het 
introduceren van een diabeteszorg-volgsysteem, in huisartspraklijkcn die deel uitmaken van 
een academisch onderzoeksnetwerk, het niveau van de diabeteszorg vergelijkbaar werd met 
uitkomsten verkregen in Randomised Clinical Trials (RCTs). Zeven jaar na de introductie 
van dit diabeteszorg-volgsysteem was het gemiddelde HbAlc aanzienlijk gedaald: van 8.2% 
naar 7.1% Slechts een kleine groep, 13% vergeleken met 41% bij de aanvang, hield een 
slecht HbAlc (> 8.5%). Het totale cholesterol daalde van 6 2 mmol/1 naar 5.4 mmol 
(p=0.001). In 1999 werden de streefwaarden ten aanzien van de hpiden bereikt bij 72% van 
de mensen, vergeleken met 52% bij aanvang. De gemiddelde bloeddruk (150/82 mmHg) en 
het percentage personen bij wie de streefwaarde werd gehaald (systolisch 54% en diastolisch 
66%)) veranderde niet. 
Deze langetermijnuitkomsten gingen gepaard met een toename van het percentage mensen 
dat op jaarcontrolc kwam: 84%) in 1999, vergeleken met 73% bi| aanvang in 1993. De 
uitkomsten in 1999 waren dus gebaseerd op een groter deel van de beschikbare patiënten. 
Aangezien echter geen patientgebonden factor bleek samen te hangen met het op jaarcontrole 
komen, zijn wij overtuigd dat de bevindingen een algemene verbetering van de diabeteszorg 
in de praktijken weerspiegelen. 
Het diabeteszorg-volgsysteem bood de mogelijkheid om personen te selecteren die mogelijk 
speciale aandacht behoeven: mensen met een slechte glycacmischc instelling ondanks 
maximale orale medicatie. In deze groep werd insulinetherapic gestart, hetgeen resulteerde in 
een klinisch significante verbetering van de glycaemische instelling (HbAlc daling van 9.5% 
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naar 7.6%, ρ < 0.001). De overgang naar insulinetherapie had een significante daling van de 
hyperglycaemische klachten (p=0.01) tot gevolg, zonder dat een toename van 
hypoglycaemische klachten optrad. Bovendien werden geen negatieve effecten van 
insulinetherapie op de functionele toestand vastgesteld. De resultaten hebben aangetoond dat 
het nastreven van strikte glycaemische controle in de huisartspraktijk haalbaar is. 
Methodologische bevindingen 
Bij het beoordelen van het verschil in levensverwachting tussen mensen met diabetes 
mellitus type 2 en mensen zonder deze aandoening, bleek dat het hanteren van andere 
selectiecriteria bij het samenstellen van de controlegroep van invloed was op de uitkomst. 
Indien in de controlegroep geen personen werden opgenomen met risicofactoren voor hart­
en vaatziekten steeg het relatieve risico op sterfte van 1.59 naar 1.67 (95% Cl 1.16 - 2.40). 
Werden uit de controlegroep personen zonder hart- en vaatziekten gekozen dan steeg dit 
relatieve risico verder naar 1.73 (95% Cl 1 2 3 - 2 46) en bij uitsluiting van ernstige 
aandoeningen naar 2.16 (95% Cl 1.46- 3.20). Het relatieve risico nam daarentegen af indien 
in de controlegroep geen personen werden opgenomen met chronisch psychosociale 
problemen (1.33, 95% Cl 0.97 -1.81). De studie toonde dat comorbiditeit en chronische 
psychosociale problematiek in controlegroepen een rol spelen bij de uitkomst van klinische 
studies. Huisartsonderzoeksnetwerken bieden de mogelijkheid deze effecten te bestuderen. 
De resultaten van het Micral-onderzoek (een semikwantitatieve dipstick-bepaling) leerde dat 
deze test alleen kan worden aanbevolen indien er een zeer strikte naleving van de uitvoering 
plaatsvindt en een herhaalde meting. De sensitiviteit (58% lot 81%) en specificiteit (87% lot 
93%) varieerden fors tussen de diverse praktijken. 
In 1992 werd een micro-albuminune, gedefinieerd als een gemiddelde albumine-uitscheiding 
in de ochtendurine > 20 mg 1"' op drie opeenvolgende dagen, gevonden bij 2 1 % van de 
mensen met diabetes mellitus type 2 (n=66) In 1998 bleek de gemiddelde verandering van 
albumine-uilscheiding in de urine bij het merendeel van de patiënten gering, echter met een 
grote spreiding. 75% van de personen zonder micro-albuminune had 6 jaar later nog steeds 
geen micro-albuminune; 40% van degenen met een micro-albuminune had 6 jaar later weer 
een normale albumine-uitscheiding Er bestond een zwakke, niet statistisch significante 
relatie tussen het hebben van micro-albuminurie bij het begin van de studie en het optreden 
van hart- en vaatziekten en sterfte in de daaropvolgende periode van 6 jaar. Cox' regressie-
analyse naar leeftijd toonde aan dat micro-albuminurie bij de aanvang van .de studie 
resulteerde in een relatief risico van 1.4 (95% Cl 0.8 - 2.7) op sterfte, van 1.2 (95% Cl 0.5 -
2.8) op sterfte ten gevolge van hart- en vaatziekten en van 1.4 (95% Cl 0.8 - 2.3) op nieuwe 
hart- en vaataandoemngen (inclusief sterfte hieraan) 
De studie voegde huisartsgeneeskundige gegevens toe aan het beloop en de voorspellende 
waarde van microalbuminurie. De kleine verandering van de albumine-uitscheiding bij het 
merendeel van de patiënten in 6 jaar tijd, gekoppeld aan de grote spreiding hiervan en de 
zwakke niet significante relatie met het optreden van sterfte en hart- en vaatziekten, 
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onderstreepten de moeilijkheid om de betekenis van micro-albuminurie goed in te schatten 
bij het behandelen van mensen met diabetes mellitus type 2 in de huisartspraktijk. 
Sterke kanten en beperkingen 
De studie beschrijft het langetermijneffect van diabetes mellitus type 2 in de huisartspraktijk 
met betrekking tol klinische eindpunten zoals sterfte en het optreden van hart- en vaatziekten. 
Aangezien het merendeel van de mensen met diabetes mellitus type 2 in de huisartspraktijk 
wordt behandeld, zijn deze gegevens van bijzonder belang voor de dagelijkse praktijk. In de 
gehele studie werden de WHO-critena (1985) met betrekking tot de diagnose van diabetes 
mellitus strikt gevolgd en was het begrip 'type 2 diabetes mellitus' duidelijk omschreven en 
gedefinieerd. Alle mensen met diabetes mellitus type 2 werden geïncludeerd zonder 
toepassing van enig selectiecriterium, dit in tegenstelling tot de inclusie in RCT's, waar 
patiënten met ernstige co-morbiditeit gewoonlijk worden uitgesloten. Onze studie bood de 
mogelijkheid de effectiviteit van de dagelijkse huisartsgeneeskundige zorg (effectiveness) te 
vergelijken met de effectiviteit van zorg (efficacy) onder onderzoekscondities.' De 
verbetering van de kwaliteit van de diabeteszorg in de deelnemende praktijken werd bereikt 
door een over jaren gespreide stapsgewijze invoering van een proces van kwaliteitsbewaking. 
Naar onze ervaring waren de volgende stappen daarbij van belang de strikte definiëring van de 
gegevens die verzameld dienden te worden, de invoering van een gestructureerde registratie, de 
systematische terugkoppeling van uitkomst van de diabeleszorggcgevcns naar de praktijken, het 
afstemmen van de aard van de terugkoppeling op de behoefte van de deelnemende huisartsen, 
het houden van toetsingsbijeenkomsten naar aanleiding van de terugkoppeling. Samengevat 
deze studie bood de mogelijkheid onderzoek te doen in een niet geselecteerde, goed 
gedefinieerde groep mensen met diabetes mellitus type 2 gedurende een periode van meerdere 
jaren in goed georganiseerde huisarlspraktijken met gemoliveerde huisartsen, die bereid waren 
belrokken te worden in een proces van kwaliteitsbewaking. 
Desalniettemin zijn er ook beperkingen. 
Ten eerste: de lien praktijken die onderdeel uitmaken van het academisch onderzoeksnetwerk 
leveren een beperkt aantal mensen met diabetes mellitus type 2, hetgeen de statistische power 
van de studie ten aanzien van relatief zeldzaam optredende klinische eindpunten beperkt. 
Ten tweede: de verzameling van gegevens vond plaats tijdens de normale dagelijkse zorg voor 
patiënten. Aangezien de deelnemende huisartsen eerst en vooral zorgdragen voor de individuele 
zorg voor de patiënten, zou de volledigheid en standaardisatie van de te verzamelen gegevens 
daar onder kunnen lijden. Om er voor te zorgen dat de gegevens toch zo volledig en 
gestandaardiseerd mogelijk verzameld werden, is dil punt regelmatig besproken tijdens de 
maandelijkse bijeenkomsten met de deelnemende huisartsen. Bovendien werd in het Huisarts 
Informatie Systeem (Promedico, Euroned) een Onderzoek Registratie Systeem (ORS) 
ingebouwd om de gegevensverzameling zo goed mogelijk te ondersteunen In dit opzichl was 
het levens van belang dal de groep van deelnemende huisartsen in de onderzoekspenode zeer 
stabiel was. Ook de supervisie van de gegevensverzameling middels de terugkoppeling naar de 
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praktijken droeg bij aan de volledigheid en standaardisatie van de gegevens. Keerzijde van deze 
ondersteuning van gegevensverzameling is dat de bereikte uitkomst van zorg niet zonder meer 
generaliseerbaar is naar de algemene huisartspraktijk. Het laat zien welke investering in de 
algemene dagelijkse praktijk nodig is om een vergelijkbare uitkomst van zorg te bereiken, 
alsmede welke uitkomst onder dergelijke gunstige omstandigheden in de huisartspraktijk 
gehaald kan worden. 
Ten derde: er moet een kanttekening worden gemaakt bij de analyse-eenheid die in deze studie 
is gehanteerd. Wij kozen voor de patiënt als analyse-eenheid. Onze resultaten toonden echter dat 
de langetermijnuitkomst van diabeteszorg in de diverse praktijken varieerde. Dit maakt 
aannemelijk dat de uitkomsten van de verschillende patiënten uit dezelfde praktijk niet 
onafhankelijk waren van elkaar. Mogelijk dat 'goede praktijken', een 'betere uitkomst' 
bereiken. 
Opmerkingen en aanbevelingen 
Benchmarking en transparantie van zorg 
De St. Vincent declaratie2 herbevestigde het belang van bewaking en evaluatie van zorg. 
Hoofdmotief achter de declaratie was de bewustwording dat in veel gezondheidssystemen artsen 
zich onvoldoende bewust zijn van de gevolgen van diabetes mellitus. Een belangrijk gevolg 
hiervan is dat de kwaliteit van de diabeteszorg in vele landen achterblijft bij wat wenselijk wordt 
geacht, terwijl het bereikte niveau van zorg zelden wordt vastgelegd.2'3 Tegenwoordig wordt 
het belang onderkend van hel regelmatig nazien van iedere patiënt, waarbij systematisch 
aandacht wordt gegeven aan de opsporing van risicofactoren en de vroeg opsporing van 
diabetes gerelateerde complicaties, gekoppeld aan een programma met mogelijkheden tot 
bijstelling en bewaking van de behandeling. Dit maakt het aanleggen van uitgebreide 
patièntregisters en het gebruik van computersystemen welhaast onvermijdelijk.4'5,6,7 
Dergelijke registers kunnen dienen als basis voor hel verzamelen van gegevens om de 
geleverde diabeteszorg transparant te maken en de zorg op een gestructureerde wijze te 
ondersteunen." Er is echter weinig bekend over de kosteneffectivileil van dergelijke 
systemen. 
De uilkomsten van dergelijke registratiesystemen moeten met voorzichtigheid beoordeeld 
worden. Ten eerste is de noemer van de uitkomsten hierbij van groot belang. Om de 
uitkomsten op waarde te kunnen schatten, moet allereerst de onderzoeksgroep waarover 
gerapporteerd wordt, duidelijk gedefinieerd zijn. Voorts moet inzichtelijk zijn welke 
mogelijke selectie is opgetreden. Welke in- en exclusiecritena zi]n gehanteerd; deze kunnen 
immers in hoge mate van invloed zijn op de gerapporteerde kwaliteit van zorg. Ook de 
weigering van patiënten om deel te nemen dan wel uitval van patiënten kan leiden tot 
vertekening. Hel is daarbij denkbaar dat weigeraars juist het meest zouden kunnen profiteren 
van een systematische bewaking van de zorg De meeste patiënten - zoals in onze studie het 
geval was - zullen toestemmen in deelname aan een gestructureerd zorgsysteem als daarover 
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voldoende uitleg wordt gegeven. Echter, een klein deel van onze patiënten wilde niet 
deelnemen of was daartoe niet in staat. Mogelijk is dit een selecte groep met meer ernstige 
co-morbiditeit of functionele beperkingen. 
Ten tweede is de toetsing van zorg vaak gericht op procesparameters en niet op 
uitkomstmaten. Het is echter de uitkomst van zorg die telt. Bovendien kan de tevredenheid 
van de patiënten over de behandeling en de effecten op de kwaliteit van leven niet worden 
afgeleid uit de standaard verzamelde biochemische en fysiologische maten. Ten derde maakt 
de omvang van het aantal mensen met diabetes mellitus type 2 dat behandeld wordt in de 
huisartspraktijk het noodzakelijk dat het leveren van gegevens voor benchmarking past 
binnen de algemene taakstelling van de eerste lijn. In dit opzicht is het gebruik van 
gestructureerde data-invoervelden van belang, zodat data-invoer tijdens de normale 
dagelijkse activiteiten mogelijk wordt. De huidige generatie huisarts-informatie-systemen die 
de Nederlandse huisartsen hanteren, biedt deze mogelijkheid niet. 
Tot slot moet benadrukt worden dat benchmarking alleen onvoldoende is om de kwaliteit van 
zorg te verbeteren. Het meten van zorg moet plaatsvinden in een bredere context waarin 
wetenschappelijk onderbouwde doelen van zorg uitgangspunt zijn. Het kwaliteitsproces dient 
te meten in hoeverre de gestelde doelen gehaald zijn, om op basis daarvan de zorg bij te 
stellen en vervolgens opnieuw te meten in hoeverre dit de doelen dichter bijbrengt.10 
Kwaliteit van leven 
Pogingen om uitstekende ziektespecifieke uitkomsten te bereiken kunnen als neveneffect 
hebben dat de kwaliteit van leven nadelig beïnvloed wordt, in het bijzonder bij de 
behandeling van chronische aandoeningen. Het meten van de invloed van behandeling op de 
kwaliteit van leven is derhalve van groot belang, niet op de laatste plaats omdat een eventuele 
negatieve invloed de compliantie van de patiënt kan verminderen. Echter, het meten van de 
kwaliteit van leven is moeilijk en de resultaten kunnen misleidend zijn." '2 Het is daarbij van 
belang het begrip 'kwaliteit van leven' in de juiste context te gebruiken Alle instrumenten 
die kwaliteit van leven meten, al dan niet ziektespecifiek, meten slechts bepaalde aspecten 
van de kwaliteit van leven. Het gebruik van de term 'kwaliteit van leven' kan de indruk 
wekken van een abstracte en filosofische benadering, terwijl in de meeste gevallen slechts 
een enkel algemeen aspect als tevredenheid en voor het overige ziektegebonden factoren 
gemeten worden.' Desalniettemin: indien duidelijk gedefinieerd en omschreven wordt welke 
aspecten gemeten zijn, kunnen dergelijke gegevens inzicht geven in de consequenties van de 
ziekte en van de behandeling die met de gebruikelijke klinische parameters niet zichtbaar 
worden. 
De meeste instrumenten die kwaliteit van leven meten, zijn tijdrovend en kunnen daarom niet 
ingepast worden in de dagelijkse praktijk. De meeste aandacht is uitgegaan naar het gebruik 
van dergelijke instrumenten in wetenschappelijk onderzoek en veel minder naar het nut 
hiervan in de dagelijkse praktijk. Een welkome ontwikkeling is onderzoek naar de 
toepasbaarheid van verkorte versies van deze instrumenten in de dagelijkse praktijk. De 
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uitkomsten van deze verkorte versies dienen daarbij vergeleken te worden met resultaten 
verkregen uit de oorspronkelijke uitgebreide vragenlijsten, om te bepalen welke informatie 
mogelijk verdwijnt.14 In dit opzicht zijn onze bevindingen met betrekking tot de 
COOP/WONCA charts van belang. 
De betekenis van richtlijnen 
Onze studie toonde de consequentie van het optreden van hart- en vaatziekten met betrekking 
tot de levensverwachting van mensen met diabetes mellitus type 2. De bevindingen 
onderstreepten het belang van systematische opsporing en controle van risicofactoren voor 
hart- en vaatziekten in de behandeling van diabetes mellitus type 2, hetgeen ook wordt 
aanbevolen in diverse richtlijnen.15 '6 '7 Het implementeren van richtlijnen blijkt echter 
moeilijk, ' en het opstellen van richtlijnen onvoldoende om de dagelijkse zorg werkelijk te 
verbeteren.1'' In ons onderzoek bleek dat het volgen van de klinische toestand van mensen 
met diabetes mellitus gedurende vele jaren, het terugkoppelen van deze gegevens naar de 
arts, het opnieuw toetsen van de uitkomst aan de hand van wetenschappelijk onderbouwde 
richtlijnen en het ondersteunen van de praktijken binnen het academisch netwerk leidden tot 
een verbeterde uitkomst van de diabeteszorg. Bovendien zal de combinatie van systematische 
bewaking, terugkoppeling en toetsing ten aanzien van relevante behandeldoelen een 'pro-
actieve' benadering van mensen met diabetes mellitus type 2 bevorderen, hetgeen een 
sleutelrol speelt bij het realiseren van succesvolle diabeteszorg.20 
Micro-albuminurie 
Terminale nierinsufficiëntie bij mensen met diabetes mellitus type 2 behandeld in de 
huisartspraklijk komt zelden voor, waarschijnlijk door de vroegtijdige sterfte aan hart- en 
vaatziekten.'1 De hoge prevalentie van diabetes mellitus type 2 zorgt er echter voor dat 
nierfalen door deze aandoening toch een kwantitatief belangrijk probleem vormt. Ongeveer de 
helft van alle mensen met diabetes mellitus die een merfunctievervangende therapie nodig 
hebben, zijn mensen met een type 2 diabetes mellitus.222"1 Het moge duidelijk zijn dat zowel 
nierdialyse als niertransplantatie een sterke negatieve invloed hebben op de kwaliteit van leven 
en gepaard gaan met hoge economische kosten. De preventie van nierfalen dan wel het 
voorkomen van een voortschrijden van dit falen, alsmede de preventie van hart- en vaatziekten, 
zijn derhalve belangrijke doelen bij de behandeling van mensen met diabetes mellitus type 2. In 
dit verband is de rol van het screenen op micro-albuminurie nog steeds controversieel.24 Hoewel 
het geaccepteerd lijkt dat micro-albuminurie beschouwd wordt als een voorloper op het ontstaan 
van een macro-albuminune (nefropathie), is de samenhang met het optreden van een 
achteruitgang van de nierfunctie omstreden. Het is daarbij onduidelijk of het opsporen en 
behandelen van micro-albuminune bij mensen met diabetes mellitus type 2 daadwerkelijk de 
prognose dan wel de kwaliteit van leven verbetert. Het is bovendien onduidelijk of een cross-
sectioneel gevonden micro-albuminune een permanent te hoog albumineverhes in de unne 
voorspelt.21 ~*lu Bovendien is de definiëring van micro-albuminune gebaseerd op het feit dat 
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een albumine-uitscheiding van 20-200 μg/min het ontstaan van een nefropathie bij mensen met 
diabetes mellitus type 1 voorspelt.27 Er is weinig wetenschappelijk bewijs dat in geval van 
diabetes mellitus type 2 dezelfde grenzen gehanteerd zouden moeten worden. Zouden bij 
mensen met diabetes mellitus type 2 hogere grenzen aangehouden moeten worden? Of zou een 
eventuele toename van het albumineverlies de belangrijkste factor moeten zijn bij het 
onderscheiden van groepen die speciale aandacht behoeven? Anderzijds is zelfs een lagere 
albumine-uitscheiding in verband gebracht met een verhoogd risico op overlijden.28 Zou de 
bewaking van de creatinineklaring een betere manier zijn om mensen op te sporen die extra 
aandacht behoeven? Dat impliceert een nog stringentere bewaking van de bloeddruk en een 
strikte controle op geneesmiddelen die de nierfunctie kunnen schaden. Al deze tekortkomingen 
in onze klinische kennis ten aanzien van de betekenis en het beloop van micro-albuminurie bij 
mensen met diabetes mellitus type 2, rechtvaardigen nader onderzoek hiernaar in de 
huisartsgeneeskunde, alleen al vanwege de enorme consequenties voor elk individu dat wordt 
geconfronteerd met een nierfunctievervangende therapie. 
Slotconclusies 
Gedurende vele jaren waren huisartsen en patiënten niet overtuigd van de verstrekkende 
consequenties van diabetes mellitus type 2 op de gezondheid en de noodzaak de zorg te 
verbeteren. Huisartsen claimden dat de meeste studies naar de invloed van diabetes mellitus 
type 2 waren uitgevoerd in klinische situaties en dat de resultaten van deze studies hierdoor een 
vertekend beeld gaven. De meeste mensen met diabetes mellitus type 2 gaven aan geen klachten 
te ervaren en ontkenden, mede daardoor, de ernst van de aandoening. Onze studie toonde 
overduidelijk de negatieve invloed aan van diabetes mellitus type 2 op de levensverwachting en 
functionele gezondheidsaspecten in een groep niet geselecteerde personen m de huisartspraktijk. 
De langetermijnresultaten van ons diabeteszorg-volgsysteem toonde de mogelijkheid om de 
uitkomst van de diabeteszorg in de huisartspraktijk te verbeteren. Het starten van 
insulinetherapie in geval van een slechte regulering van de bloedglucosewaarden ondanks 
maximale orale medicatie, resulteerde in een klinisch significante verbetering van de instelling, 
zonder nadelig effect op de functionele gezondheidsaspecten. De resultaten toonden aan dat de 
gewenste effecten van behandeling, preventie en uitstel van hart- en vaatziekten door middel 
van een striktere regulering van de bloedglucosewaarden, in de huisartspraktijk haalbaar zijn. 
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1. Computertechnologie ondersteunt de kwaliteit en continuïteit van zorg door inzicht in 
resultaten permanent binnen handbereik van de huisarts te brengen {dit proefschrift) 
2. Vroegtijdige detectie en behandeling van cardiovasculaire risicofactoren bij mensen 
met diabetes mellitus type 2 is niet alleen belangrijk ter verbetering van de 
levensverwachting van deze mensen maar evenzeer ter voorkoming van functionele 
beperkingen (dit proefschrift). 
3. Monitoring van groepen patiënten met eenzelfde ziekte is een sensitief instrument 
voor de detectie van individuen met een afwijkend beloop (dit proefschrift). 
4. In de huisartspraktijk kan ruim 90% van de mensen met diabetes mellitus type 2 
adequaat worden behandeld (dit proefschrift). 
5. Insuline kan bij mensen met diabetes mellitus type 2 leiden tot goede 
bloedsuikerwaarden, maar biedt daarvoor geen garantie (dit proefschrift). 
6. Het uitsluiten van microalbuminune is eenvoudiger dan het aantonen ervan (dit 
proefschrift). 
7. Hoewel terminale niennsufficiëntie een zeldzame aandoening is, blijft het voorkómen 
daarvan onverminderd van belang. 
8. NHG-nchtlijnen dienen niet alleen op wetenschappelijke houdbaarheid te worden 
getoetst, maar evenzeer op praktische haalbaarheid en kosten. 
9. Transparante diabeteszorg dient betaald te worden. 
10. Schaarste aan huisartsen bedreigt de diabeteszorg. 
11. Klagen loont: krakende wagens gaan langer mee {dit proef schrift). 
12. 0.3 fte + 0.7 fte Φ 1.0 fte 
13. Ruimte geven aan kinderen betekent grenzen stellen. 
14. De macht van de euro wordt zichtbaar als omwille van exportbelangen, geen huis- en 
dierentuindieren ingeënt mogen worden tegen mond- en klauwzeer. 
15. 'Wees zuinig met zeker' is een waardevol adagium in het dagelijks leven, de 
huisartsenzorg en de wetenschap. 


